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This thesis consists of 6 chapters. The first two chapters are reviews which are meant to 
introduce into the airways. Then, questions of my experimental works and hypothesis are 
followed. Finally, I mentioned three papers which have been published as original papers. 
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SUMMARY 
Multiple distinct viruses and bacteria have been detected in the airways. Recently, it has been 
confirmed that the microbiome of allergic individuals differ from those of healthy subjects, showing 
a close relationship with the type 2 response in airway disease. Chronic rhinosinusitis with nasal 
polyps (CRSwNP) is a chronic inflammatory upper airway disease. A smaller population of Chinese 
CRSwNP patients, but 85% of European CRSwNP patients show a Th2-biased and eosinophilic 
inflammation. An increase in colonization with Staphylococcus aureus (S. aureus) and the presence 
of S. aureus enterotoxin-specific IgE antibodies have been demonstrated in the mucosa of CRSwNP 
subjects in comparison with control or chronic rhinosinusitis without nasal polyp (CRSsNP) patients. 
Moreover, a high prevalence of viruses such as human rhinovirus (HRV), human respiratory 
syncytial virus (HRSV), influenza virus (IFV), and herpes simplex virus is also observed in 
CRSwNP mucosa. However, it is unknown to which extent viruses and bacteria directly impact on 
the Th2 response in CRSwNP.  
CRSwNP is also characterized by a deficit in fork head box P3 (Foxp3)+ T regulatory (Treg) cells 
in European and Chinese patients. Therefore, restoring Treg cell efficiency may be a useful strategy 
to inhibit Th2 responses in CRSwNP. In this thesis, we established human nasal ex vivo infection 
models to study the inflammatory response after infection, and we aimed to confirm the hypothesis 
that microbes affect the Th2 response in CRSwNP. Furthermore, we investigated ways to inhibit 
Th2 responses in CRSwNP tissue by reinforcing the suppressive function of Treg cells.  
In the first model, we have demonstrated that S. aureus infection increased IL-33, Thymic stromal 
lymphopoietin (TSLP), IL-5, and IL-13 expressions in CRSwNP tissue accompanied by elevated 
expressions of the TSLP and IL-33 receptors, which were predominantly expressed on CD3+ T cells. 
Healthy inferior turbinate (IT) tissue did release TSLP after S. aureus infection, but not type 2 
cytokines. Compared to S. aureus, Staphylococcus epidermidis did not induce any IL-33, TSLP and 
type 2 cytokine release in neither CRSwNP nor healthy IT tissues. Increased levels of IL-33 and 
TSLP were also induced by S. aureus in BEAS-2B bronchial epithelial cells, associated with an 
activation of nuclear factor-κappaB (NF-κB) pathways. Blocking toll-like receptor (TLR) 2 using a 
specific antagonist CU-CPT22 reduced the effect of S. aureus infection on release of TSLP and IL-
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33 and the activity of NF-κB signaling in BEAS-2B cells, pointing to the role of TLR2 in this 
activation.  
In the thesis we also have demonstrated that CRSwNP tissue showed a significant deficit in IFN-
γ and IL-17 release within 24 to 72h after herpes simplex virus 1(HSV1) infection, while releasing 
significantly more pro-inflammatory cytokines including IL-1β and TNF-α during the same time 
frame. These findings were associated with significantly higher viral invasion scores at 48 and 72h 
in CRSwNP mucosa compared to those for IT. There was a significantly higher spontaneous release 
of IL-5 at 24h and 48h in CRSwNP vs. IT, but this was independent from HSV1 infection. These 
observations support the hypothesis that CRSwNP tissue provides an inadequate defense against 
virus infection when compared to healthy tissue, which may contribute to more and longer 
symptoms upon acute infection, but also to the persistence of inflammation in CRSwNP tissue. In 
CRSwNP tissue, we have observed that suppressor of cytokine signaling 3 (SOCS3) gene and 
protein expression was up-regulated in inflammatory cells, whereas Foxp3 gene and protein 
expression was down-regulated. For the first time we showed that nasal mucosal Treg cells co-
express both proteins. Switching off the expression of SOCS3 in human airway mucosa resulted in 
Foxp3 up-regulation, whereas inducing it in a cancer cell line PANC-1 led to Foxp3 down-
regulation. We also found that phosphorylation of signal transducer and activator of transcription 3 
(STAT3) was decreased in inflamed mucosa, and we hypothesized that SOCS3 may be responsible; 
indeed, phosphorylation of STAT3 increased upon silencing SOCS3 expression in inflamed mucosa 
and decreased upon SOCS3 plasmid transfection in PANC-1 cells. Finally, the expression of the 
Th2 cytokine IL-5 decreased in CRSwNP tissue upon silencing SOCS3 expression using siRNA 
transfection, indicating that this intervention is functional; increased Foxp3 expression in CRSwNP 
tissue inhibited the Th2 response. 
In summary, we have demonstrated that S. aureus contributes to the Th2 response via the 
epithelial cell derived cytokines TSLP and IL-33 in CRSwNP tissue. CRSwNP tissue shows a 
significant deficit in the defense against viruses such as HSV1 and HRV, and against S. aureus 
infection when compared to healthy tissue, which may contribute to the persistence of inflammation 
in CRSwNP tissue. Silencing SOCS3 expression inhibits IL-5 cytokine expression in CRSwNP 
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tissue via an up-regulation of Foxp3 expression, which may represent an innovative therapeutic 
strategy in Th2-biased CRSwNP disease. 
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SAMENVATTING  
Verschillende virussen en bacteriën werden gedetecteerd in de luchtwegen. Recent onderzoek heeft 
bevestigd dat het microbioom van allergische individuen verschilt met dat van gezonde individuen, 
wat aantoont dat er een nauwe relatie bestaat met een type 2 (Th2) immuunrespons in 
luchtwegaandoeningen. Chronische rhinosinusitis met neuspoliepen (CRSwNP) is een chronische 
ontstekingsziekte van de bovenste luchtwegen. Een kleiner deel van de Chinese CRSwNP patiënten, 
maar 85% van de Europese CRSwNP patiënten hebben een Th2 gemedieerde en eosinofiele 
inflammatie. In CRSwNP patiënten werd een verhoogde kolonisatie met Staphylococcus aureus (S. 
aureus) en een verhoogde aanwezigheid van specifieke antibodies tegen S. aureus enterotoxine 
waargenomen, vergeleken met gezonde individuen en patiënten met chronische rhinosinusitis 
zonder poliepen. Daarenboven werd in het mucosa van CRSwNP patiënten een hoge prevalentie 
van virussen zoals het humane rhinovirus (HRV), humane respiratory syncytial virus (HRSV), 
influenza virus (IFV) en herpes simplex virus waargenomen. Nochtans is het onbekend in welke 
mate virussen en bacteriën een directe impact hebben op de Th2 respons in CRSwNP. 
CRSwNP wordt ook gekarakteriseerd door een defect in fork head box P3 (Foxp3)+ T regulatory 
(Treg) cells in Europese en Chinese patiënten. Daarom zou het herstel van de efficiëntie van deze 
Treg cellen een bruikbare strategie kunnen zijn om de Th2 respons in CRSwNP patiënten te 
inhiberen. In deze thesis werd een humaan nasaal ex vivo infectie model ontwikkeld om de 
inflammatoire respons na infectie te bestuderen en met het doel de hypothese te bevestigen dat 
micro-organismen de Th2 respons kunnen beïnvloeden in CRSwNP.  Daarenboven werden er 
manieren gezocht om de Th2 respons in CRSwNP weefsel te inhiberen via het versterken van de 
suppressieve functie van de Treg cellen. 
In het eerste model, hebben we aangetoond dat S. aureus infectie zorgt voor een verhoging van IL-
33, thymic stromal lymphopoeitin (TSLP), IL-5 en IL-13 expressie in CRSwNP weefsel. Dit effect 
ging gepaard met een verhoogde expressie van de TSLP en IL-33 receptoren die voornamelijk op 
CD3+ T cellen tot expressie kwamen. Inferiour turbinate weefsel van gezonde individuen (IT) 
toonde een vrijstelling van TSLP na S. aureus infectie, maar niet van type 2 cytokines. Vergeleken 
met S. aureus, zorgde Staphylococcus epidermidis niet voor de inductie van IL-33, TSLP en type 2 
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cytokines in CRSwNP of gezond IT weefsel. In BEAS-2B werden eveneens verhoogde levels van 
IL-33 en TSLP geïnduceerd na infectie met S. aureus. Dit was geassocieerd met een activatie van 
de nuclear factor-kappaB (Nf-kB) pathway. Het blokkeren van toll-like receptor (TLR) 2 met de 
specifieke antagonist CU-CPT22, verminderde het effect van S. aureus infectie op de vrijstelling 
van TSLP en IL-33 en de activiteit van NFkB signaling in BEAS-2B cellen. Dit wijst op een rol van 
TLR2 in deze activatie. 
In de thesis werd ook aangetoond dat CRSwNP weefsel een significant defect in de vrijstelling van 
IFN-γ en IL-17 vertoont 24 tot 72 uur na herpes simplex virus infectie, terwijl significant meer pro-
inflammatoire cytokines waaronder IL-1β en TNF-α werden vrijgesteld in ditzelfde tijdsframe. 
Deze bevindingen waren geassocieerd met significant hogere virale invasie scores na 48 en 72 uur 
in CRSwNP mucosa, vergeleken met deze van de IT. Er was een significant hogere spontane 
vrijgave van IL-5 na 24 en 48 in CRSwNP versus IT, maar dit was onafhankelijk van HSV1 infectie. 
Deze observaties ondersteunen de hypothese dat CRSwNP weefsel voor een inadequate verdediging 
zorgt tegen virus infectie wanneer met die vergelijkt met gezond weefsel. Dit kan bijdragen tot meer 
een langere symptomen bij acute infectie maar ook tot de persistentie van de inflammatie in 
CRSwNP weefsel. Een op regulatie van suppressor of cytokine signalling 3 (SOCS3) genexpressie 
en proteïne expressie in inflammatoire cellen van CRSwNP weefsel werd geobserveerd, terwijl 
Foxp3 gen- en eiwit expressie een down regulatie vertoonden. Wij toonden voor de eerste keer aan 
dat nasale mucosale Treg cellen beide proteïnen tot expressie brengen. Het uitschakelen van de 
expressie van SOCS3 in humane luchtwegmucosa resulteerde in een op regulatie van Foxp3, terwijl 
het induceren in de kanker cel lijn PANC-1 leidt tot Foxp3 down regulatie. De fosforylatie van 
signal transducer and activator of transcription 3 (STAT3) was verminderd in ontstoken mucosa en 
we stelden als hypothese dat SOCS3 hiervoor verantwoordelijk zou kunnen zijn. Inderdaad, de 
fosforylatie van STAT3 was verhoogd na silencing van SOCS3 expressie in ontstoken mucosa en 
verminderd na SOCS3 plasmide transfectie in PANC-1 cellen. De expressie van het Th2 cytokine 
IL-5 was verminderd in CRSwNP weefsel na silencing van SOCS3 expressie door midden van 
siRNA transfectie. Dit toont aan dat deze interventie functioneel was: verhoogde Foxp3 expressie 
in CRSwNP weefsel inhibeerde de Th2 respons. 
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Samengevat, hebben we aangetoond dat S. aureus bijdraagt aan de Th2 respons door middel van de 
epitheliale cel geproduceerde cytokines TSLP en IL33 in CRSwNP weefsel. CRSWNP weefsel 
toont een significant gebrek in de defensie tegen virussen zoals HSV1 en HRV, en tegen S. aureus 
infectie vergeleken met gezond weefsel, wat kan bijdragen aan de persistentie van de inflammatie 
in CRSwNP weefsel. Het silencen van SOCS3 expressie inhibeert de expressie van het IL-5 
cytokine in CRSwNP weefsel via een op regulatie van Foxp3 expressie, wat een mogelijk 
innovatieve therapeutische strategie voorstelt voor de behandeling van Th2 gemedieerde CRSwNP. 
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VIRUSES AND BACTERIA 
IN TH2 BIASED ALLERGIC AIRWAY DISEASES 
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Viruses and bacteria in Th2 biased allergic airway disease 
Feng Lan, Nan Zhang, Elien Gevaert, Luo Zhang, Claus Bachert 
 
Abstract: 
Allergic airway diseases are typically characterized by a type 2-biased inflammation. Multiple 
distinct viruses and bacteria have been detected in the airways. Recently, it has been confirmed that 
the microbiome of allergic individuals differs from those of healthy subjects, showing a close 
relationship with the type 2 response in allergic airway disease. In this paper, we summarize recent 
findings on the prevalence of viruses and bacteria in type 2-biased airway diseases and on 
mechanisms employed by viruses and bacteria in propagating type 2 responses. The understanding 
of the microbial composition and post-infectious immune programming is critical for the 
reconstruction of the normal microflora and immune status in allergic airway diseases.  
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Introduction 
The role of environmental and gastrointestinal pathogens in allergic airway inflammatory pathology 
(whether protective or provocative) has been widely studied. The hygiene hypothesis proposes that 
a low prevalence of childhood asthma is associated with exposure of infants to a microbe-rich 
environment1,2. A low diversity of the gut microbiome in early infancy precedes asthma at school 
age3. However, the Copenhagen Prospective Studies on Asthma in Childhood recently suggested 
that individual susceptibility and inflammatory consequences after infection, rather than the specific 
microbial trigger, are associated with school-age asthma development4. Therefore, understanding 
the microbial composition and post-infectious immune programming in type 2-biased airway 
diseases are important for therapeutic interventions in the future. Allergic asthma, allergic rhinitis 
and chronic rhinosinusitis with nasal polyps (CRSwNP) are typical airway disorders that are 
characterized by a type 2-biased inflammation. In this review, we summarize the prevalence of 
viruses and bacteria in type 2-biased airway diseases, on the mechanisms employed by viruses and 
bacteria in propagating type 2 responses and the impact of T helper 2 (Th2) cytokines on the defense 
against infections.  
The prevalence of viruses in the airways 
Viral infections starting from the nasopharynx in early life are reportedly associated with an 
increased risk of developing asthma later in life (Table1). Viral infections that affect allergic upper 
airway diseases can also lead to acute asthma exacerbations in the lower airways5. To clarify the 
prevalence of viral communities in the development of asthma, nasopharyngeal samples were 
obtained from infants at scheduled visits at 2, 6, and 12 months of age, or within 48h after onset of 
an acute respiratory infection (ARI) during the first year of life in the extension of the Childhood 
Asthma Study6. The most common viruses found in the nasopharynx of healthy children during ARI 
were human rhinovirus (HRV) (40%) and human respiratory syncytial virus (HRSV) (11%)6. 
Among those viruses, HRV-C rather than the other HRV subtypes or HRSV, which was detected in 
nasopharynx of healthy children during ARI accompanied by wheezing symptoms, was positively 
associated with later chronic wheezing among all children and particularly for those who were 
atopic by 2 years6. In a recent study, HRSV and HRV induced lower respiratory tract infections in 
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412 pediatric patients up to the age of 3 years were associated with the development of wheezing 
and exacerbations7. In addition, pediatric patients with HRV induced wheezing were more likely to 
develop subsequent recurrent wheezing and asthma during the following 3 years7. Both HRV and 
HRSV are well known risk factors for subsequent wheezing or asthma development in infancy, but 
they also have specific susceptibilities according to their age. HRV infection carries a markedly 
higher risk for persistent wheezing in younger infancy (under 2 years of age)8, while HRSV 
infections are related to the development of asthma in children at school age9. 
Table 1. The prevalence of viruses in airways. 
HRV: human rhinovirus; HRSV: human respiratory syncytial virus; IFV: influenza viruses; VNT: virus 
neutralization test; RT-PCR: reverse transcription polymerase chain reaction; 16S rRNA: 16S ribosomal 
RNA, m: month; y: year. 
In hospitalized children aged between 3 to 16 years, HRV and HRSV were the most frequent 
viruses in nasopharynx secretion during asthma exacerbations10. Similarly, a Japanese group also 
demonstrated that HRSV was related to wheezing episodes and was more frequent in patients with 
Characteristic of subjects Sample source Identification 
techniques 
The common viruses Ref. 
Healthy infants (<12m)  
during acute respiratory 
infection 
nasopharynx 
secretion 
RT-PCR;  HRV (40%); 
HRSV (11%);  
6-7 
Asthmatic children (3-16y)  
during asthma exacerbation 
nasopharynx 
secretion 
RT-PCR;   
VNT;     
HRV (30.3%);              
HRSV (40.9%);              
IFV (15.9%);               
HSV-1 (56.8%); 
10-13 
Asthmatic adults during 
asthma exacerbation 
nasopharynx  
secretion 
RT-PCR; HRV-A,B,C (10.4%)        
HRSV-A (10.4%); 
Metapneumovirus (6.3%); 
14 
Chronic rhinosinusitis  
patients 
nasal tissue or 
epithelial cell 
scraping; 
RT-PCR; Picornavirus (29%);       
HRSV (15%);              
IFV (20%);            
Parainfluenza viruses-3(18 %); 
15-16 
Allergic rhinitis patients nasal swab RT-PCR; HRV (14.1%); 23 
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a history of asthma11. Besides HRSV and HRV, also influenza viruses (IFV) were involved in 
asthma exacerbations in children particularly with atopic sensitizations, but not in non-atopic 
children12. In atopic Turkish children with asthma and allergic rhinitis, significantly higher herpes 
simplex type 1 (HSV-1) IgG seropositivity was detected in the serum than in the matched non-atopic 
group13, suggesting a possible relationship between pediatric allergic airway diseases and HSV-1 
infections. In adults, higher incidences of HRV A/B/C, HRSV A, and metapneumovirus infections 
were observed in nasopharyngeal swabs during asthma exacerbations Corynebacterium 
pneumonia14.  
 The rate of picornavirus, HRSV, IFV, and parainfluenza viruses was significantly increased in 
CRS patients compared with that seen in controls (64% vs. 30%)15. Particularly, HRV was the only 
virus that shared a significant increase in infection rate in both nasal lavage and epithelial cells 
scrapped from nasal inferior turbinate of CRS patients vs. controls. On the contrary, a high rate of 
this virus was also found in epithelial cells scrapped from the nasal middle meatus of Chinese 
CRSwNP patients, but with no significant difference when compared with controls16. Thus, 
sampling from different places of the nose contributes to the different results. Concordantly, a high 
prevalence of HRV was also present in sinus tissues in Brazilian CRS patients, and there was a peak 
of detection during the autumn and winter seasons, when respiratory viruses are far more prevalent17. 
Unfortunately, CRS was not further differentiated in that study. In contrast to Th2-biased 
inflammatory characteristics of CRSwNP, CRSsNP often exhibits a Th1-cell inflammation pattern18. 
Due to their different inflammatory patterns, it is necessary to characterize the prevalence of viruses 
in each subgroup of CRS in the future. 
  Allergic rhinitis is an allergic inflammation of the upper airways, and it is also a known risk factor 
for wheeze and asthma. In general, asthma occurs in 10–40% of patients with allergic rhinitis, 
whereas allergic rhinitis occurs in 20–80% of patients with asthma19,20. Interestingly, both the cross-
sectional survey of Singaporean and the Pollution and Asthma Risk: an Infant Study birth cohort 
studies demonstrated that allergic rhinitis may start as early as in the first 2 years of life21,22. In early 
childhood, HRV was the most frequent virus detected in nasal swab samples of prolonged/recurrent 
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rhinitis23. Interestingly, HRV-positive infants with recurrent rhinitis had a higher rate of wheeze 
compared to HRV-negative infants23.  
Table 2. The prevalence of bacteria in airways. 
RT-PCR: Reverse transcription polymerase chain reaction; 16S rRNA: 16S ribosomal RNA, m: month; 
y: year. 
Subjects Sample Identification 
technique 
Bacterial species Ref. 
Healthy infants (2m)      
without acute respiratory 
infection  
nasopharynx 
secretion 
16S rRNA  
pyrosequencing; 
bacterial culture; 
Staphylococcus (41%); 
Corynebacterium(22%);       
(main bacteria)    
Alloiococcus (14%);       
Moraxella (9%);        
Haemophilus (9%);         
6, 29 
Healthy infants (12m)       
without acute respiratory 
infection  
nasopharynx 
secretion 
16S rRNA  
pyrosequencing;  
Moraxella(41%);  
Alloiococcus(26%);            
(main bacteria)  
Staphylococcus (11%); 
Corynebacterium (12%);   
6, 
Healthy children (24m) nasopharynx 
secretion 
bacterial culture; Streptococcus pneumoniae (72.8%); 
Moraxella catarrhali (78.6%); 
Haemophilus influenzae (57.3%); 
Staphylococcus aureus (3.9%) 
25 
Healthy adults (18-66y) middle meatus  
swab 
16S rRNA 
pyrosequencing; 
RT-PCR; 
Staphylococcus epidermidis (96.4%);                     
Staphylococcus aureus (67.9%); 
Propionibacterium acnes (92.9%);  
34
Asthmatic patients (>18y) 
during asthma exacerbation 
nasopharynx   
swab 
RT-PCR Streptococcus pneumoniae (18.8%); 
Haemophilus influenzae (12.5%); 
14 
Chronic rhinosinusitis  
without asthma patients  
sinus swab 
(ethmoid region) 
RT-PCR Staphylococcus (19.3%); 
Fusobacterium (9.0%);  
35,36 
Chronic rhinosinusitis with 
asthma patients  
sinus swab  
(ethmoid region)  
RT-PCR Staphylococcus (28.4%);    
Ralstonia (8.2%);       
Acinetobacter (2.3%);                            
35,36 
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Similar to childhood allergic rhinitis, an abundance of respiratory viruses, especially HRV, was 
detected in nasal lavage samples of adult perennial allergic rhinitis patients, but respiratory viral 
infection was independently correlated with symptom scores24.  
The prevalence of bacteria in the airways 
Bacterial community composition is a strong determinant of general health and disease, as well as 
a potential modulator of inflammatory processes contributing to airway diseases. Here bacteria 
which affect airway diseases are listed in Table 2. In infants, the nasopharynx microbiome is 
qualitatively dominated by six common genera: Haemophilus, Streptococcus, Moraxella (those 
three genera are common in ARI), Staphylococcus, Alloiococcus and Corynebacterium (more 
common in healthy samples)6, which is consistent with previous studies in children25,26 and in 
adults27. Similarly, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, 
Streptococcus pyogenes and Staphylococcus aureus (S. aureus) were also observed in nasopharynx 
swabs of Asian infants28. However, the Asian infants had a higher colonization of S. aureus (88.9–
100.0%) than in other studies at the first year of life, and 50% of S. aureus was methicillin-resistant 
S. aureus28. Nevertheless, the composition of microbial communities seems unstable over time. 
Early colonization typically involved Staphylococcus or Corynebacterium, which later was replaced 
by Moraxella or Alloiococcus in healthy infants, indicating that the composition of microbiome 
undergoes dynamic changes6. Whether the early microbiome dynamic change is related with later 
allergic airway diseases, requires more research. Clearly neonatal colonization with Haemophilus 
influenzae, Moraxella catarrhalis and Streptococcus pneumoniae had a strong correlation with 
subsequent recurrent wheeze and childhood asthma6,29,30. Evidence was also available that S. aureus 
acted as a risk factor for asthma development in children and young adults, but not in older adults31-
33. It is an evident that bacterial organisms act as important contributors to asthma exacerbations. A 
study of the bacterial composition of the nasopharynx in adult asthmatic patients indicated that 
Streptococcus pneumoniae infection was also associated with asthma exacerbations in clinical 
practice14.  
 In CRS, inflammation development takes place in the middle meatus. A high prevalence of 
Staphylococcus epidermidis (96.4%), S. aureus (67.9%), and Propionibacterium acnes (92.9%) was 
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found in middle meatus specimens of healthy adults34. Similarly to healthy adults, bacteria such as 
Pseudomonas, Staphylococcus, and Streptococcus were numerically dominant in sinus tissues of 
CRS patients35. Interestingly, a higher abundance of Staphylococcus, Acinetobacter, Pseudomonas 
aeruginosa, and Ralstonia species, and a lower level of Prevotella, Fusobacterium and 
Campylobacter species were detected in CRS patients with concomitant asthma than in CRS 
patients without asthma35,36. Additionally, patients with abundant expression of Corynebacterium 
at the time of endoscopic surgery had an optimal outcome, while patients with high S. aureus had a 
suboptimal outcome35. Coherently, an increase of nasal S. aureus carriage and the presence of S. 
aureus enterotoxin-specific IgE antibodies have been described in the mucosa of CRSwNP subjects 
and perennial allergic rhinitis patients33,37, and this is even higher in CRSwNP patients with asthma 
comorbidity and aspirin sensitivity. The further analysis on antibiotics resistance bacteria in allergic 
rhinitis highlighted that an increase of methicillin assistant staphylococcus aureus burden provides 
an insight into the difficulty of eradicating the bacterium38.  
Viruses and type 2 responses in allergic airway diseases 
HRV, as one of the most common viruses in human airways, is associated with the development 
and exacerbation of allergic asthma. Epithelial cell derived cytokines such as IL-33, thymic stromal 
lymphopoietin (TSLP) and IL-25 are critical in propagating a type 2 immune response by affecting 
Th2 cells, type 2 innate lymphoid (ILC2) cells and dendritic cells39. HRV infections induce mucosal 
IL-33 production in vivo, which can further initiate type 2 cytokine release from Th2 cells or ILC2 
cells40. HRV-induced IL-25 amplified type 2 responses via activation of IL-25 receptors on murine 
Th2 cell, ILC2s and basophils41. Elevated levels of TSLP in allergic asthma subjects positively 
correlated with the severity of asthma42, but so far there is no direct evidence showing the effect of 
HRV infection on TSLP production. In a recent study, CD11b+ exudative macrophages bearing M2 
macrophage markers have been identified as a new source for IL-13 production in a OVA asthma 
mouse model after HRV infection43. 
  Respiratory syncytial virus (RSV), a member of the paramyxoviridae family, is also associated 
with type 2 responses in allergic airway diseases. An increased level of IL-13 was observed in the 
lungs of BALB/c mice, mediated by IL-33 and TSLP production after intranasal RSV incubation44, 
21 
 
45. Furthermore, the interactions between a glycosyltransferase lunatic fringe and Notch ligands 4- 
Notch were reportedly responsible for the augmented Th2 inflammation in mouse during RSV 
asthma exacerbations46. Thus, IL-33, TSLP and Notch signaling might be the possible therapeutic 
target in RSV-induced Th2 responses. In addition to the classical Th2 cells and ST2L+ cells, a novel 
human subset of IL-6Rαhigh effector memory CD8+ T cells was identified to exclusively release IL-
5 and IL-13 after HRSV infection47. IL-6Rαhigh effector memory CD8+ T cells were detected in high 
numbers in the peripheral blood of asthma subjects47, suggesting a role of the cells in promoting 
Th2 responses in asthma (Figure 1).  
 
 
 
 
 
 
 
 
Figure 1: The role of viruses induces type-2 immune response in airways. Human airway epithelial 
cells produce IL-33, IL-25 in response to human rhinovirus (HRV)41-42. IL-33 and IL-25 subsequently 
drive IL-13 (yellow balls) and IL-5 (green balls) productions via binding to their receptors ST2L and IL-
25R respectively on Th2 cells, type 2 innate immune cells (ILC2s) and basophils42. Human respiratory 
syncytial virus (HRSV) also can induce type-2 cytokine release in airways from IL-6Rαhigh effector 
memory CD8+T cells48.  
 
  Similarly, IFV may induce the release of IL-33 from Natural killer T cells and alveolar 
macrophages in mice, leading to a robust IL-5 release from ILC2 cells48. Not only viruses but also 
viral nucleotide analogues can contribute to IL-13 expression by triggering mast cells in mice49. 
Taken together, the effect of viruses including HRV, RSV and IFV on type 2 responses are well 
established in the lower airways, but their role in upper airways awaits further investigation. 
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Bacteria and type 2 responses in allergic airway diseases 
Airway bacteria such as Moraxella, Corynebacterium pneumonia, Streptococcus pneumoniea and 
S. aureus are associated with the development and exacerbations of asthma, but the underlying 
molecular mechanisms have not yet been unveiled. Endonasal instillation of ovalbumin (OVA) plus 
staphylococcal enterotoxin B (SEB) induced a murine pulmonary inflammation, which is 
characterized by an increase in the number of eosinophils and the production of Th2 cytokines50. It 
has been reported that exposure of mouse splenocytes and peritoneal macrophages to CpG 
oligodeoxynucleotides from Streptococcus thermophilus enhanced IL-33 expression51, which may 
further initiate Th2 responses. However, not all bacteria exhibit the ability to enhance Th2 response; 
Haemophilus influenzae infection synergized with OVA mouse model of asthma elevates Th17 
responses, not Th2 responses52.  
 
 
 
 
 
 
 
 
Figure 2: The role of bacteria induces type-2 immune respones in airways. After binding to toll-like 
receptor 2 (TLR2), Staphylococcus aureus (S. aureus) induces type 2 cytokines productions via thymic 
stromal lymphopoietin (TSLP) and IL-33 release from human airway epithelial cells (data not published). 
The staphylococcal enterotoxin B (SEB) induces type 2 cytokine releases by affecting the differentiation 
of T helper (Th) 2 cells and IL-6Rαhigh CD8+cells48. 
In upper airways, our group has proved that SEB induces considerable release of Th2-
associated cytokines including IL-4, IL-5 and IL-13 and also enhances eosinophilic inflammation 
in human nasal tissues53-56 (Figure 2). Without the effect of the enterotoxin, CRSwNP tissue 
exposure to S. aureus alone led to IL-5 expression via TLSP and IL-33 productions (data not 
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published). Even though IL-6Rαhigh effector memory CD8+T cells are involved in virus-induced 
Th2 response, they also trigger IL-5 and IL-13 expressions in response to the bacterial superantigens 
SEB and TSST-147. In mouse, an adhesion molecule of S. aureus “iron-regulated surface 
determinant A’’ mediated IL-4 secretion from splenocytes57. In summary, the effect of bacteria on 
Th2 response especially in upper airways implicates an important role of bacteria in allergic airway 
diseases.  
Type 2 cytokines upon viral and bacterial infection  
In allergic airway diseases, IL-4 is critical for Th2 cell differentiation and causes a switch to IgE 
production by differentiating B cells58. IL-5 is associated with eosinophil development and 
activation59. IL-13 regulates IgE isotype switching in B cells, as well as activating mast cells, 
eosinophils, and neutrophils60,61. As mentioned above, microbial infection can induce type 2 
cytokine releases. Simultaneously, type 2 cytokines also can exaggerate inflammation in response 
to respiratory infection. IL-4 and IL-13 pre-treated human airway epithelial cells promoted higher 
expression of pro-inflammatory chemokines such as IL-8, CXCL9, CXCL10, CXCL11 in response 
to polyriboinosinic: polyribocytidylic acid stimulation62. IL-13 enhanced goblet cell differentiation 
63, and the induction of mucous metaplasia inhibited ciliogenesis and ciliary beat frequency, thereby 
changing the apical membrane structure which increased susceptibility of human airway epithelium 
to HRV16 infection63, 64. HRV16 infection in turn resulted in further dysfunction of ciliary clearance 
and hyper-secretion of mucus, aggravating the inflammation in airways65. Additionally, IL-4 and 
IL-13 increased HRV16 replication by reducing the interferon producing capacity of human 
bronchial epithelial cell line66. Thus, type 2 cytokines increase susceptibility to viral infection in 
airways via changing the epithelial structure and the production of interferons. 
In the upper airway, a disruption of the tight junctions such as occludin and zona occludens-1, 
and an irregular expression pattern were observed in the IL-4–stimulated primary nasal epithelial 
cells67. Zona occludens-1 expression became discontinuous in human nasal epithelial cells exposed 
to the S. aureus conditioned media68, however, there is no direct evidence showing a correlation 
between the reduced tight junctions and higher susceptibility to bacterial infection. Indeed, IL-13, 
not IL-4, markedly down-regulated antimicrobial protein psoriasin expressions in human nasal 
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epithelial cells69, which resulted in an increase in susceptibility to bacterial infection. In contrast, 
IL-4 and IL-13 exposure to human bronchial epithelial cells during mucociliary differentiation 
contributed to the antimicrobial defense against Pseudomonas aeruginosa infection via induction 
of antimicrobial peptide human beta defensin-270. Therefore, the multifaceted role of Th2 cytokines 
has been shown in anti-microbial protein production.  
 
 
Figure 3: Targets to block type 2 immune responses in airways with viral and bacterial infections. 
Microorganisms, epithelial cell derived cytokines such as TSLP and IL-33, type 2 cytokines such as IL-
4, IL-5, IL-13 and their receptors are targets to inhibit type 2 biased immune response in airways 79-82. 
TLR2: toll-like receptor, siRNA: small interfering RNA, TSLP: thymic stromal lymphopoietin, TSLPR: 
TSLP receptor; ST2L: IL-33 receptor; ILC2: type 2 innate immune cells; IgE: immunoglobulin E; 
GATA3 DNAzyme: GATA binding protein 3 deoxyribozymes. 
 
Ways to block type 2 responses in allergic airway disease 
As mentioned above, there is a link between infection and type 2 response. Type 2 cytokines and 
their binding receptors, mechanisms of inducing type 2 cytokines during infection and 
microorganisms become potential targets to block human type 2 responses allergic airway diseases 
(Figure 3). Intra-nasally pretreated anti-IL-4 and anti-RSV siRNAs reduced eosinophils in broncho-
alveolar lavage fluid of a mouse model of asthma during asthma exacerbations71. It provides 
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promising “silencing” techniques such as siRNA and DNAzyme against viruses or bacteria to be 
used in human model to diminish type 2 allergic immune responses. Likewise, non-cytotoxic 
anthraquinone derivatives ameliorated IL-4 and IL-13 expressions through de-phosphorylation 
AKT in an OVA-asthmatic mouse model with RV exacerbations72. Anti-IL-25 antibody had a 
similar inhibitory effect on Th2 inflammation induced by murine pneumonia viruses, but it also 
promoted a Th17 response73. Based on the findings in a mouse model, monoclonal blocking 
antibodies against type 2 cytokines are used in asthmatic patients in clinic trails. Targeting IL-13 
(lebrikizumab) or both IL-4 and IL-13 signaling have demonstrated therapeutic benefits for treating 
moderate-to-severe asthma patients with increased eosinophils or periostin74,75. Additionally, 
neutralization of IL-5 by mepolizumab is a promising intervention for patients with severe 
eosinophilic asthma76, 77. Furthermore, blocking a subunit of IL-4 receptor by dupilumab can also 
efficiently inhibit both IL-4 and IL-13 signaling in patients with persistent, moderate-severe asthma 
78. Omalizumab, a humanized monoclonal antibody to block interaction between IgE and high 
affinity IgE receptor (FcεRI), can significantly improve the lung functions and markedly advance 
asthma control of severe asthma patients79. FcεRI activation is also associated with reciprocal down-
regulation of typeⅠinterferon production during viral asthma exacerbations80. Thus, omalizumab 
blocks the type 2 response in allergic asthma and consequently enhances viral clearance by restoring 
type I interferon production. The expression and the production of Th2 cytokines is also controlled 
by the transcription factor human GATA binding protein 3 (GATA3) which is relevant for the 
differentiation of Th2 lymphocytes. Applied in a human asthma model, GATA3 specific-
deoxyribozymes (DNAzyme), a DNA molecule docks the GATA3 RNA expression, led to the 
reduction of Th2 response81. In the upper airways, the monoclonal antibodies mepolizumab, 
reslizumab, omalizumab and dupilumab have been subjected to proof-of-concept studies. Those 
therapeutic approaches efficiently suppress Th2 immune responses and also may counteract the 
consequences related to it in terms of deficits in mucosal defense mechanisms82. MiR-143, with a 
direct inhibitory role on IL-13 receptor α1 chain expression, suppresses IL-13-induced 
inflammatory cytokine and mucus production in nasal epithelial cell from allergic rhinitis patients83. 
Besides the use of monoclonal antibodies against Th2 cytokines and their receptors, interferon-
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β produced a strong and consistent abrogation of Th2 cytokine production from human periphery 
blood mononuclear cells in the presence of HRV infection84. MiR-143 with a direct inhibitory role 
on IL-13 receptor α1 chain (IL13Rα1) expression, suppressed IL-13-induced inflammatory cytokine 
and mucus production in nasal epithelial cell from AR patients83. Specific immunotherapy for 3 
months also can inhibit Th2 response in allergic rhinitis patients by modulating T cell 
immunoglobulin mucin domain molecule 4 (TIM4)/TIM1 interaction on dendritic cells85.  
The interaction between virus and bacteria 
Most of the investigations focused on the effect of virus alone or bacterium alone in allergic airway 
diseases, whereas little is known about viral and bacterial co-infection. In the clinic, virus and 
bacteria co-infections increased the readmission risk of asthmatic patients86, and a high frequency 
of co-infections was observed in asthma exacerbation patients14. In mouse model, preceding virus 
infection may enhance the bacterial adherence such as galectins for pneumococcal adhesion87, and 
depress the recruitment of neutrophils and natural killer cells which play an important role in the 
bacterial clearance88,89. Conversely, exposure of influenzae to primary human epithelial cells 
significantly enhanced the binding of HRV16, probably through up-regulation of intercellular 
adhesion molecule and toll-like receptor -3 expression90. Our recent study also showed that herpes 
simplex virus type 1 infection facilitates invasion of S. aureus into the nasal mucosa and CRSwNP 
tissue91. In humans with acute respiratory illnesses, however, children with HRSV and Mycoplasma 
pneumonia co-infection had more severe airway inflammation than those with HRSV infection 
alone92, bacteria (influenzae, catarrhalis and pneumoniae) are more likely to be detected 
among virus-negative specimens compared to virus-positive burden93. Similarly, mice with pre-
symptomatic influenza infection are less susceptible to secondary methicillin-resistant S. aureus 
infection94, due to the persistence of IL-13 signaling that was advantageous for resolving 
methicillin-resistant S. aureus infection. These observations suggest a profound deference of host 
defense upon different pathogen species infection. Further investigations addressing potential 
interactions between specific viruses and bacteria in allergic airway diseases are therefore warranted.  
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Perspectives  
In this paper, we have summarized the evidence for viruses and bacteria to initiate or maintain type 
2 responses in the airways. Those infectious agents are commonly associated with Th1 and Th17 
responses. We here stress that apart from allergens, specific germs and viruses also may play a 
critical role in the induction of type 2 immune responses. We assume that not one single event will 
be enough to initiate and certainly not to maintain Th2 inflammation, but rather that multiple hits 
are necessary over time, involving microbes, allergens and environmental factors (Figure 4).  
 
 
Figure 4 Multiple hits may initiate or maintain Th2 biased immune response in airways. Low 
numbers of viruses and /or bacteria may persistently exert pressure as colonizers, biofilm formers or 
intra-mucosal intruders. And high number of microbes may hit the airway mucosa during an acute 
infection exacerbation and result in plenty of Th2 cytokine release. The balance among Th1, Th2, and 
Th17 responses, the status of airway mucosa and the some environment are also involved in Th2 biased 
immune response initiation or maintenance in airways. HRV: human rhinovirus, HRSV: human 
respiratory syncytial virus, S. aureus: staphylococcus aureus, Th: T helper.  
 
The impact of such events probably depends on the quantity of viruses and/or bacteria and the time 
course, e.g. high numbers of microbes may hit the airway mucosa during an infection, and low 
numbers may persistently exert pressure as colonizers, biofilm formers or intra-mucosal intruders. 
Furthermore, the immune status of the airway mucosa will make a difference, with a Th1/Th17 
biased mucosa being more resistant to Th2 pressure than an already Th2-biased inflammatory status. 
As we have discussed, these different Th milieus may co-exist, and thus the balance among Th1, 
Th2, and Th17 responses may determine the course and speed of disease development. Finally, a 
Th2 response may establish itself within the mucosa, which leads to further negative effects; a Th2 
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bias indices an insufficiency to defend the mucosa against viral and bacterial infections. For example, 
our group has demonstrated that S. aureus can induce type 2 cytokine release in CRSwNP tissue, 
but not in healthy control mucosa (publication submitted).    
Some literatures indicated that there is no difference of the prevalence rate of viruses and bacteria 
between allergic airway diseases and controls. The following limitations have to be taken into 
account: Although culture-independent techniques have the ability to detect more microbes than 
culture techniques, culture-dependent methods so far remain a better approach for microbiome 
isolation. In this review, only a cited paper from Michael Inouye’s6 group has carried out additional 
culture dependent approach in parallel to reduce the possibility of false findings. Some another 
factors such as samples from different part of airways, the influence of medication especially the 
use of antibiotics, an acute respiratory infection occurred in the intervening period between 
sampling, and sampling from different seasons also affect results. Therefore, standardized 
microbiome identifications are very necessary to gain useful data.  
In children, the most common viruses found in respiratory tracts are HRV and HRSV during 
acute infections, which are associated with a high risk for subsequent wheezing and asthma 
exacerbation. Thus, HRSV or HRV vaccination has been recommended in high-risk children for 
prevention of childhood asthma. However, bacteria such as Haemophilus and Staphylococcus were 
abundant after applying the seven-valent pneumococcal conjugate vaccine, targeting Streptococcus 
pneumoniae serotypes25. Thus, the subsequent bacterial composition when implementing viral 
vaccines needs careful monitoring.  
In the absence of effective anti-viral therapies, targeting pathogenic bacteria for manipulating the 
microbiome by antibiotics may be an alternative approach. In contrast, several epidemiological 
studies reported that antibiotic consumption in the first year of life was associated with a risk of 
asthma in later life6, 95. Due to the “common mucosal response” concept which means alterations in 
immune function of the respiratory tract are linked to the immunomodulatory activity of the gut 
microbiome, oral administration of probiotics was used for treating allergic airway diseases by 
changing the gut microbiome3. Some investigations have shown that oral administration of 
probiotics and prebiotics may benefit allergic rhinitis patients96-98. Moreover, the local nasal 
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administration of Lactococcus lactis NZ9000 can affect local and systemic immune responses 
against Streptococcus pneumoniea99. Probiotics seem a potentially therapeutic approach for allergic 
airway diseases, but there are still many controversial issues to be solved. The meta-analysis by 
Elazab et al. has demonstrated that early probiotic administration does decrease atopic sensitization, 
but it does not reduce the risk of developing asthma100. The differences in study design and the 
usage of different probiotic strains or combinations can lead to completely different results. 
Adequately controlled experiments with standardized criteria using specific strains, dosages and 
timing are anticipated to provide more insight.  
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Regulatory T cell in allergic airway diseases 
Feng Lan, Nan Zhang, Elien Gevaert, Luo Zhang, Claus Bachert 
 
Abstract: 
Allergic airway diseases are characterized by a skewed T helper 2 (Th2) response and decreased 
numbers of regulatory T (Treg) cells. Treg cells potentially suppress deleterious activities of effector 
T cells and maintain a state of tolerance against antigens in airway mucosa. Therefore, 
understanding the role of Treg cells in allergic airway diseases is crucial for therapeutic 
interventions. This paper briefly reviews the naturally occurring Treg (nTreg) cells and different 
phenotypes of induced Treg (iTreg) cells in allergic airway diseases. Recent findings on their 
identification, generation, migration, and suppressive function as well as their modulation in airway 
diseases are also discussed.  
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Introduction 
The airway mucosa is constantly exposed to airborne allergens and exogenous particles. The 
immune system analyzes and appropriately responds to these exposures, forming a state of immune 
tolerance. Regulatory T (Treg) cells play a crucial role in tolerance induction in airway mucosa. A 
deficiency or dysfunction of Treg cells may cause allergic airway inflammatory diseases with 
exacerbated effector T cell proliferation and cytokine production against foreign pathogens. 
Allergic airway diseases discussed in this study are chronic rhinosinusitis (CRS), allergic rhinitis 
(AR) and allergic asthma. CRS, representing an inflammation of the nose and paranasal cavities, is 
further divided into two subgroups: CRS with nasal polyps (CRSwNP) and CRS without nasal 
polyps (CRSsNP). European CRSwNP, AR and allergic asthma are characterized by a skewed T 
helper 2 (Th2) response, elevated IgE concentrations and decreased number of Treg cells1-3. The 
reinforcement suppressive function of Treg cells is therefore regarded as a plausible strategy to 
modulate Th2 immune response. However, adoptive transfer of naturally occurring Treg (nTreg) 
cells in a mouse model of asthma did not provide satisfactory results4. The two main reasons could 
be: i) difficulty in obtaining sufficient numbers of Treg cells for therapeutic interventions since Treg 
cells constitute 1%–2% of CD4+T cells, ii) alteration in the phenotypes and functional characteristics 
of nTreg cells caused by repetitive T cell receptor (TCR) stimulation 5. In addition, the inflammatory 
environment with pro-inflammatory cytokines such as IL-6 and TNF-α could also convert nTreg 
cells into Th17 cells6,7. Although nTreg cells and induced Treg (iTreg) cells share a similar function 
in both prevention and treating allergic response in an ovalbumin (OVA) induced mouse model of 
asthma8, iTreg cells have superior functional characteristics including resistance to Th17 conversion 
and anti-apoptosis9. Therefore, adoptive transfer of iTreg cells may be a promising therapeutic 
approach in allergic airway diseases. The hypothesis, however, awaits more investigations to be 
confirmed. In this review, we will focus on recent findings on identification, generation, migration, 
and suppressive function modulation of nTregs and different types of iTregs such as 
CD4+CD25+Foxp3+iTreg cells, Type 1 regulatory T (Tr1) cells, Foxp3+ invariant Natural Killer T 
(iNKT) cells, and Foxp3+ gammadelta (γδ) T cells, which are closely associated with airway 
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inflammatory diseases. The biomarkers for different Treg cells identification are listed in the Table 
1.  
Table 1. The phenotypes of regulatory T cells in airway disease. 
nTreg, natural occurring regulatory T cell; iTreg, induced regulatory T cell; γδ, gammadelta; Tr 1, 
Type 1 regulatory T cell; Foxp3, fork head box p3, CTLA, cytotoxic T lymphocyte-associated 
antigen-4; GITR, glucocorticoid-induced tumor necrosis factor receptor; TCR, T cell receptor LAG-
3, lymphocyte activation gene3; ICOS, Inducible T cell co-stimulator; PD1, programmed cell death-
1. 
Naturally occurring regulatory T cells  
Cell type Cell markers Origins Ref. 
nTreg cell CD4+, CD25+, CD127low, 
Foxp3high, CD6- GITR, 
CTLA-4 (activated nTreg) 
Thymus; 
Foxp3−CD25+nTreg cell precursor 
18-20, 
23-24 
CD4+CD25+Foxp3
+ iTreg cell 
CD4+, CD25+, CD127low, 
Foxp3high, 
Periphery; 
CD4+CD25-T cells  
 
18-22 
Tr1 cell IL-10+, Foxp3-, 
ICOS+, PD-1+, CD49b+, 
LAG-3+, CD226+ 
Periphery; 
conventional or naïve or CD4+T cell 
(human);  
CD4+CD62L−Foxp3− cell; (human 
and mouse) 
59-63 
Foxp3+ iNKT cell CD25+, Foxp3+, CD1d+, 
invariable TCR, CTLA4- or 
GITR- 
Periphery;  
iNKT cells include in: 
CD1d+Vα14Jα18 with Vβ8, or Vβ7 
or Vβ2 cell (mouse);  
CD1d+Vα24Jα18Vβ11 cell (human); 
74-75, 
81 
Foxp3+ γδ T cells TCRγδ+, CD25+, Foxp3+ Periphery;                 
human central memory γδ T 
cells(CD27+CD45RA−);      
mouse splenocytes;   
93-94 
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Regulatory T cells are generally divided into nTreg cells and iTreg cells. nTreg cells mature in the 
thymus under the influence of interactions between TCR and autoantigens; while iTreg cells are 
generated from their precursors in the periphery of secondary lymphoid organs or mucosa tissues. 
The generation of nTreg cells in thymus requires two steps: TCR/CD28 and RelB-dependent 
medullary thymic epithelial cells control Foxp3−CD25+nTreg cell precursors generation; IL-2 
signaling subsequently induces the generation of Foxp3+CD25+nTreg cells from the 
Foxp3−CD25+nTreg cells10-13. IL-2 is dispensable for nTreg cells development in thymus14, whereas 
it is indispensable for nTreg cell peripheral survival 11. The proliferation of nTreg cells in periphery 
is associated with an increased TCR-mediated signaling or CD28 co-stimulation15-17.  
To identify nTreg cells, biomarkers CD4+, CD25+, CD127low and Foxp3high are required. A high 
expression of Helios, neuropilin-1(Nrp1), programmed cell death-1(PD-1) and Swap70 on nTreg 
cells is also used to distinguish nTreg cells from iTreg cells18-20. However, conflicting data shed 
doubt on their specific roles21,22. Recently, human nTreg cells were reportedly characterized by low 
CD6 expression 23. Moreover, the active form of nTreg cells selectively expresses markers such as 
glucocorticoid-induced tumor necrosis factor receptor (GITR) and cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4)24. 
nTreg cells are generated in the thymus, mediating their suppressive function in lymphoid organs 
and peripheral inflammatory sites25. Therefore, knowing its migration from thymus to secondary 
lymphoid organs and further to periphery in vivo helps us understand the underlying mechanisms 
of nTreg-mediated suppression. nTreg cells are primed by interacting with antigens in draining 
lymph nodes, and then the active nTreg cells concomitantly control the proliferation of responder T 
cells26. Although mouse nTreg cells express both chemokine receptor (CCR)4 and CCR727, the 
migration of nTreg cells to lymph nodes to interact with antigens largely depends on CCR7 not 
CCR428. Thus, without priming in lymph nodes, an increase of CCR7-/- nTreg cells in lung tissue of 
mouse inefficiently suppresses Th2 and Th17 responses induced by house dust mite (HDM)29. In 
periphery, CCR4 and CCR7 were involved in the migration of mouse nTreg cells at different stages 
of airway allergic response. CCR7 mediated Treg cells migration to the lymph nodes is essential 
during an allergen sensitization phase, whereas CCR4-dependent Treg cell homing to lungs or even 
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to broncho-alveolar lavage fluid is required to suppress a recall response to an inhaled allergen and 
consecutive allergic pulmonary inflammation30, 31. Consistent with mouse studies, human subjects 
with asthma had an increase in CCR4 expression in nTreg cell of lungs after the segmental allergen 
challenge30. In nasal tissue, the number of nTreg cells trafficking towards nasal airway mucosa 
decreased in CRSwNP subjects in comparison with controls due to the reduced chemotactic 
response of nTreg cells to CCL132. Hereby, modulation of chemokine receptor expression on nTreg 
cells or chemotactic response of nTreg cells may restore the deficiency or dysfunction of nTreg cells 
in airway allergic diseases.  
CD4+CD25+Foxp3+ induced regulatory cells 
Surface markers of CD4+CD25+Foxp3+iTreg cells are similar to nTreg cells. Distinguishing 
CD4+CD25+Foxp3+iTreg cell from nTreg cell or other T cell subtypes has been widely hampered 
due to lack of specific markers. However, Helios, Nrp1, PD-1 and Swap70 described above are still 
useful for CD4+CD25+Foxp3+iTreg cell identification. 
In a TCR-transgenic mouse model, CD4+CD25+Foxp3+iTreg cells were generated in the absence 
of nTreg cells, implicating that the generation of iTreg cells may be independent of nTreg cells in 
vivo33. Both mouse and human CD4+CD25-T cells were converted into CD4+CD25+Foxp3+iTreg 
cells by triggering TCR in the presence of transforming growth factor beta (TGF-β) or in 
combination with IL-234, 35. 1, 25-Dihyroxyvitamin D3 binding to the vitamin D response elements 
in the Foxp3 conserved non-coding sequence region, also can induce Foxp3 expression in human 
CD4+CD25-T cells36. Additionally, mouse lung tissue resident macrophages contributed to the 
conversion of CD4+T cells into CD4+CD25+Foxp3+iTreg cells in a TGF-β and retinoic acid 
dependent manner37. The induction of Foxp3 is critical for CD4+CD25+Foxp3+iTreg cell 
generations. Therefore, a better understanding of Foxp3 regulation is useful for obtaining more 
iTreg cells in periphery. Foxp3 hypermethylation was associated with pediatric asthma 
exacerbations or asthma development in response to air pollutant exposures38,39. Reportedly, DNA 
hypermethylation inhibitors boosted Foxp3 expression and increased the expansion of 
CD4+CD25+Foxp3+iTreg cells to alleviate airway inflammation in the OVA-sensitized mice40. 
Recently, our group demonstrated that suppressor of cytokine signaling 3 (SOCS3) indirectly 
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regulates Foxp3 expression in human CRSwNP tissues41, which may also contribute to the induction 
of Foxp3+iTreg cells in allergic upper airway diseases. In comparison to nTreg cells, 
CD4+CD25+Foxp3+iTreg cells efficiently decreased Th2 asthmatic inflammation and reduced 
specific IgE levels in the airways42, 43, which confirms that CD4+CD25+Foxp3+iTreg cells could be 
a possible therapeutic approach for airway allergic inflammatory diseases.  
iTreg cells are induced in periphery or ex vivo, however understanding their migration to 
peripheral inflammatory sites is also important for  immune homeostasis. Defective trafficking 
properties of CD4+CD25+Foxp3+iTreg cells have been found in mucosal of the OVA-induced 
persistent hyper-responsiveness (AHR) model. Intranasal transfer of aeroallergen loaded airway 
mucosal dendritic cells from naïve rats into AHR susceptible rats during prolonged aerosol 
challenge markedly boosted subsequent iTreg cells accumulation in the airway mucosa44. In other 
words, changing the properties of antigen presenting cells will attract more 
CD4+CD25+Foxp3+iTreg cells to peripheral inflammatory sites. This may be relevant to 
immunotherapy for allergic disease by up-regulating the expansion of specific Treg populations via 
repeated mucosal exposure to allergens.  
Different from nTreg cell, CD4+CD25+Foxp3+iTreg cells exhibit non-Ag-specific bystander 
activity in vitro. Both nTreg cells and iTreg cells suppress responder T cells and antigen presenting 
cells (APCs) via two ways: cell-cell contact or soluble inhibitory cytokines. Active nTreg cells kill 
CD4+ and CD8+ T cells and other cell types in a perforin-dependent, Fas-FasL-independent 
manner45,46. After activation, nTreg cells are less dependent on co-stimulatory signals in comparison 
to responder T cells. Thus, the blockage of B7/CD28 and CD40/CD40L signals alters the balance 
between responder T cells and nTreg cells, which is in favor of nTreg cells activities in the OVA 
induced mouse model of asthma47,48. Both the responder T cells and APCs can be the targets of Treg 
cells, but the mechanisms of Treg cells on the responder T cells are different from those on dendritic 
cells (DCs). The interactions of CTLA-4 on nTreg cells with CD80/CD86 on DCs are an important 
pathway by which nTreg cells could mediate their suppressive function on DCs in vitro49. IL-10 
produced from Ag-specific iTreg cells, not CTLA-4, plays a critical role in down-regulation of 
CD80/CD86 on DCs in CTLA-4 deficient mice50. More recently, the adhesion molecule lymphocyte 
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activation gene-3(LAG-3) was also reportedly involved in the suppressive activity on nTreg cells 
by binding to MHC class II on DCs and interfering with the maturation and immune stimulatory 
capacity of DCs51. Surprisingly, no appreciable difference in ability to suppress T cell proliferation 
in vivo between wild type nTreg cells and LAG-3-/- nTreg cells has been described52. LAG-3-/-T cells 
show a relatively persistent ability to be suppressed, which means effector T cells with LAG-3 
expression are more susceptible to suppression52. Apart from cell-cell contact, inhibitory cytokines 
IL-10, TGF-β, adenosine and IL-35 are associated with the suppressive function of nTreg cells and 
iTreg cells53-55. IL-10 and adenosine showed their suppressive properties by influencing the 
maturation and co-stimulatory molecule expression of DCs53, 54; TGF-β maintains Foxp3 expression 
in Treg cells 56. In allergic airways of mice, nTreg cells exhibit a more effective suppressive function 
towards Th1 than Th2 responses via cAMP57. IL-35 produced by mouse nTreg cells was responsible 
for suppressing IL-17 dependent AHR58 .  
Type 1 regulatory T cells 
Tr1 cells are an inducible regulatory T cell population in human CRSwNP tissue and mouse lung 
tissue, characterized by the abundant production of IL-10 and absence of Foxp3 expression59, 60. 
Inducible T cell co-stimulator (ICOS), PD-1, CD49b, LAG-3 and CD226 are expressed on Tr1 cells, 
although, none of them can be regarded as a specific marker61,62. At present, the co-expression of 
CD49b, CD226 and LAG-3 are used for human and mouse Tr1 cell purification and isolation63. 
Human Tr1 cells are induced from naive CD4+T cells or conventional CD4+T cell precursors 
triggered by IL-27 and IL-10 respectively64, 65. CD3 and CD46 stimulation in the presence of IL-2 
contributes to human Tr1 cells conversions from CD4+T cells66. However, poor proliferation of Tr1 
cells was observed owing to a high rate of cell death67. Nasal administration of CD3 antibodies 
induced Tr1 cells from CD4+CD25- T cells depending on IL-27 secreted by upper airway resident 
DCs68. In addition, a component of extracellular matrix, hyaluronan, promoted Tr1 cell generations 
from human or mouse conventional CD4+CD62L−Foxp3− T cell precursors69. nTreg cells are also a 
candidate for Tr1 cell inductions upon the stimulation of CD46 and TNF-α70, implicating that the 
local environment is important for the plasticity of nTreg cells. In AR patients, the number of Tr1 
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cells and not nTreg cells were decreased in peripheral blood71. Thus, Tr1 cell induction in local 
nasal tissue could be an attractive target in inhibiting the allergic inflammatory response in AR. 
The suppressive function of Tr1 cells is mainly mediated by inhibitory cytokines, specifically IL-
10 and TGF-β72. However, neutralizing antibodies against IL-10R and TGF-β cannot completely 
diminish Tr1 cell suppressive functions72. Reportedly, human Tr1 cells specifically lyse APCs via 
granzyme B and perforin, which confirms that cell-cell contact is also involved in the suppressive 
activity of Tr1 cells73. 
Foxp3+ invariant Natural Killer T cells 
iNKT cells are unique CD1d-restricted innate-like T cells, which shares the properties of both T 
cells and natural killer cells. Type 1 iNKT cells have been better described than type 2 iNKT cells 
owing to their invariable TCRs (Vα14Jα18 α-chains paired with a limited number of β-chains Vβ8, 
Vβ7, Vβ2 in mice, Vα24Jα18 α-chains paired with Vβ11 chain in  humans)74, 75. Activated iNKT 
cells in the mice models of asthma or peripheral blood from asthmatic patients are capable of 
producing Th1, Th2, or Th17 cytokines76-80. When Foxp3 is induced, Foxp3+iNKT cells obtain 
immunosuppressive properties, with the expression of CD25 but not necessarily CTLA4 or GITR81. 
Thus, combined markers (CD25+, Foxp3+, CD1d+ and invariable TCRs) can be used for human and 
mouse Foxp3+iNKT cell identification.  
Human Foxp3+iNKT cells were induced from CD25+CD1d+iNKT cells in the presence of TGF-
β plus rapamycin81. In contrast to an earlier study, it was found that IL-10 plus rapamycin rather 
than TGF-b induced Foxp3 expression in freshly isolated peripheral blood Vα24+Vβ11+iNKT cells 
82. However, Foxp3+iNKT cells which are generated from different ways show the same suppressive 
activity. Recently, it was also reported that the selected human iNKT cell clones (CD4+, double 
negative) acquired a dramatic increase of Foxp3 expression upon anti-CD3 stimulation; the 
induction of Foxp3 was also observed in a CD4+ iNKT cell clone upon PMA-ionomycin 
treatments83.  
Although, Foxp3+iNKT cells inhibit the proliferation of conventional CD4+ cells in a cell-cell 
contact manner, the mechanisms mediating the suppressive function is still unclear81. Foxp3+iNKT 
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cells are excluded from lymph nodes and preferentially migrate to peripheral tissues in association 
with the expression of CD103 cells84. However, further investigations are still required to detail the 
migration of Foxp3+iNKT cells. 
Foxp3+ gammadelta T cells  
γδT cells, with γδ TCR expression, directly recognize conserved non-peptide antigens and lipids 
independent of MHC/peptide complexes, which is different from classical αβ T cells. According to 
the usage of Vδ-chain, γδT cells can be mainly divided into 2 subsets Vδ1 and Vδ2; the different 
TCR arrangement directly affects their eventual principle tissue of residence. In humans, Vδ1 cells 
with Vγ1 or Vγ4 are mainly located in lung and nasal mucosa85, 86; Vδ2 cells with Vγ9 account for 
50–95% of circulating γδ T cells in the peripheral blood87. In mice, Vγ1 and Vγ4 are present in the 
lymphoid tissues and Vγ1, Vγ4, and Vγ6 are present in the lungs88. The surface markers CD45RA 
and CD27 further classify Vδ2+ or Vδ1+ cells into naive (CD45RA+CD27+), central memory 
(CD45RA-CD27+), effector memory (CD45RA-CD27-), and effector (CD45RA+CD27-) statuses89. 
Untill now, the role of γδT cells in allergic airway diseases remains ambiguous. Mouse Vγ1+δ1 T 
cells promoted airway inflammation or AHR by enhancing the systemic IgE response. In contrast, 
Vγ4+δ1 T cells alleviated AHR, the Th2 airway allergic response and eosinophilic infiltrations in 
OVA sensitized mice90,91. Increased γδT cells were found in the peripheral blood of moderate/severe 
house dust mite positive AR patients, which was positively correlated with IL-17 secretions92. 
Surprisingly, inflammatory γδT cells obtain a suppressive function when Foxp3 is induced, and 
different phenotypes of Foxp3+γδT cell have different surface markers. Human Foxp3+Vδ2 T cells 
express CD25+ CD27+ CD45RA+93, while human Foxp3+Vδ1 T cells exhibit CD25+ CD27+ 
CD45RA- expression94. Similar to human Foxp3+γδT cell, TCRγδ and CD25 are also used for mouse 
Foxp3+γδT cell isolation95. Recently, a novel mouse regulatory γδ T cell CD39+γδ T cell, with the 
expression of CD25, CD27, CD39 and CD122 but not Foxp3, has been identified 
both in vitro and in vivo96. Taken together, TCRγδ, CD25 and Foxp3 are used for human and mouse 
Foxp3+γδ T cell identification. 
  Casetti et al. 93 reported that the induction of Foxp3+Vγ9Vδ2 T cells from human central memory 
γδ T cells (CD27+CD45RA−) in the presence of Ag stimulation and cytokines (TGF-β1, IL-15) had 
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an anti-proliferative effect on CD4+ T cells. Quite surprisingly, freshly isolated Vδ2γδ T cells 
without Foxp3 expression also can suppress the activity of responder CD4+CD25−αβ T cell via the 
interactions between CD86 on Vδ2 T cells and CTLA-4 on αβ T cells97. Therefore, it seems that 
Vγ9Vδ2 T cells with or without Foxp3 expression have suppressive functions. However, whether 
they have their suppressive function in vivo or allergic airway diseases awaits further investigations. 
In mice, γδTCR and TGF-β stimulation induced Foxp3+γδT cell from mouse splenocytes95.  
The inducible Foxp3+Vδ1 Tregs showed a potent anti-proliferative effect on CD4+ T cells via 
cell-cell contact, although, cytokine-dependent mechanism might also play a role in suppressive 
functions 93. The question whether Foxp3+Vδ1 γδ regulatory T cells are capable of mediating 
suppressive functions to CD4+γδ T cells is yet to be answered. 
The effect of allergic airways treatments on Treg cells 
Treg cells are very important for Th2 response alleviation in allergic airway diseases. At the same 
time, clinical therapy may also affect the role and the number of Treg cells in allergic disease. In 
the treatment of allergic airway disease, corticosteroids provide temporary suppression of 
inflammatory cytokines and immune cells. Pre-incubation of human nTreg cells with fluticasone 
propionate increased the subsequent suppressive actions of nTreg cells in allergen-stimulated 
CD4+CD25-T cells by an IL-10-dependent mechanism98. Allergen-SIT has been used as a 
desensitizing therapy for allergic diseases. HDM-specific immunotherapy (SIT) can induce specific 
Tr1 cells that abolish HDM-induced proliferation of Th1 and Th2 cells, as well as their cytokine 
production99. Beside Tr1 cells, CD4+CD25+Foxp3+iTreg cells generated by Allergen-SIT also 
contribute to the suppression of airway eosinophilia in OVA-mouse model of asthma upon OVA 
challenge100.  
Conclusions 
Most of the current information relating to the role of Treg cells in allergic airway diseases focuses 
on asthma. Allergic asthma is mainly characterized by a Th2-biased response, thus the findings of 
Treg cells in asthma may also have important implications for understanding their role in other Th2 
biased diseases, such as AR and CRSwNP. However, with an increasing emphasis on the 
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distribution and contribution of Treg cell subtypes in allergic diseases, extensive research from 
asthma to upper airway allergic disease or from animal models to human samples is required in the 
near future.  
Innate T cells such as iNKT cells and γδ T cells are located in the airway mucosa101. T Activated 
iNKT cells in peripheral blood from asthmatic patients are capable of producing Th1, Th2, or Th17 
cytokines76-80. Increased γδT cells were found in the peripheral blood of moderate/severe house dust 
mite positive allergic rhinitis patients, which was positively correlated with IL-17 secretions92. 
Therefore, attempts to restrict the activities of iNKT cells or γδT cells in allergic airway disease by 
converting them into Foxp3+iNKT cells or Foxp3+γδT cells will be beneficial for treating allergic 
airway diseases.  
Over the last 5–10 years, the role of nTreg cells and CD4+CD25+Foxp3+iTreg cells in airways 
has been studied extensively. Certainly, understanding the appropriate markers to identify nTreg 
cells and iTreg cells is essential to study their frequency and function. However, research 
demonstrated the role of Treg cells in the airways without distinguishing their subtypes, especially 
of nTreg cells and CD4+CD25+Foxp3+iTreg cells. Thus, it is important to define the different 
subtypes of Treg cells and further investigate their ability to modulate inflammation in allergic 
airway diseases. As mentioned above, Tr1 cells, Foxp3+iNKT cells and Foxp3+γδT cells do suppress 
allergic responses (Figure1). Generation of human Treg cells and enhancing their functions in the
 
Figure 1. Different subtypes of regulatory T cell (Treg) in allergic airway disease. Allergic airway 
disease is caused by inappropriate Th2-driven immune responses to viruses, bacteria, and allergen in the 
49 
 
environment. nTregs are generated in thymus thereafter , they migrate from thymus to periphery lymph 
node or from periphery lymph node to human airway tissue which is mediated by different chemokine 
receptors (CCRs). The interactions between nTreg cells and DCs could mediate their suppressive 
function on dendritic cells (DCs), at the same time nTreg cells can be activated after interactions. In turn, 
active nTreg cells suppress T effector (Teff) cells via two ways cell-cell contact and soluble inhibitory 
cytokine release such as TGF-β, IL-10, IL-35. Induced regulatory T (iTreg) cells, generated from 
CD4+CD25- T cell in periphery, obtain suppressive function similar as nTreg cells. Another three iTreg 
cells such as type 1 regulatory T (Tr1) cell, Foxp3+ invariant Natural Killer T (iNKT) cells, 
Foxp3+gammadelta(γδ)T cells can also be induced in human airway tissues. They do show a potent anti-
proliferative effect on CD4+ T cells, however, the mechanisms are partially unveiled. 
 
airways may be an attractive concept. In parallel, a defective migration also leads to the deficiency 
and dysfunction of nTreg cells; thus, enhancing the migration of nTregs or iTregs by increasing the 
chemotactic response may be a possible strategy for allergic airway disease treatment. Of 
importance, the environment of Treg cells has influence on peripheral Treg cells maintenance. Thus, 
comprehensive treatment, considering iTreg cell generation and their suppressive function and 
enhancement of migration to restore Treg cell efficiency in allergic airway disease should be useful 
to modulate allergic responses in the future.  
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The definition, diagnosis of CRS. Chronic rhinosinusitis (CRS) is a heterogeneous group of 
diseases of the nose and the paranasal sinuses that lasts for three months or longer. According to the 
European position paper on rhinosinusitis and nasal polyps1, symptoms of CRS may include the 
following: nasal obstruction, nasal secretion and/or post-nasal drip, headaches and/or facial pains, a 
reduction of smelling for more than 12 weeks during the last year while at least one of the first two 
mentioned symptoms should be observed. The clinical diagnosis of CRS is currently based on 
symptoms and duration of symptoms, clinical examinations, nasal endoscopy and CT-scan. With 
reference to the endoscopic findings, the difference is made between the clinical phenotypes of CRS 
without nasal polyps (CRSsNP) and CRS with nasal polyp (CRSwNP)1. Histologically, CRSsNP is 
characterized by fibrosis of the mucosa and the basal membrane, while CRSwNP is characterized 
by an important edema with deposition of albumin and the development of pseudocysts. The clinical 
pattern of symptoms is overlapping in patients with CRSsNP and CRSwNP. The differentiation of 
the inflammatory subtypes based on T helper (Th) cells allows a more differentiated classification 
according to pathomechanical principles into so-called endotypes within the clinical phenotypes 
which can finally be used to define innovative therapeutic approaches. 
Epidemiology of CRS. Recently, the Global Allergy and Asthma Network of Excellence2 published 
a first multicenter prevalence study on chronic rhinosinusitis based on 56,000 questionnaires by 19 
centers in 12 European countries. A random sample was also submitted to clinical examination by 
a specialist in order to confirm the diagnosis. The investigation came to the conclusion that the 
prevalence of CRS in Europe amounts to 10.9%, between 6.9 and 27.1% in different European cities 
3. In the USA, the prevalence of CRS is slightly higher 4. Among all CRS patients in the USA, about 
20–33% suffer from CRSwNP, 60–65% suffer from CRSsNP, and 8–12% from allergic fungal 
sinusitis4. CRS was more common in smokers than non-smokers3. Co-morbidities such as asthma 
and aspirin hypersensitivity are frequent in nasal polyposis.  
Therapeutic options. Medical treatment consisting of nasal corticosteroids and antibiotics is the 
first step in treatment. Topical intranasal corticosteroids have shown to be safe and effective in 
reducing polyp size5. There anti-inflammatory effect is localized and their systemic absorption has 
been shown to be negligible, however, efficacy is limited. The use of systemic corticosteroids has 
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been widely used in treatment of CRSwNP, however systemic side effects limit its usefulness. 
Adverse effects of corticosteroid use include diabetes, peptic ulcer disease, hypertension, and 
osteoporosis. Nowadays, functional endoscopic sinus surgery has become the standard procedure to 
restore sinus ventilation and drainage by opening the key areas while preserving sinus mucosa, 
according to the European position paper on rhinosinusitis and nasal polyps1. However, recurrence 
after surgery is frequent, and other solutions are urgently need. Immunoglobulin E (IgE) antibodies 
directed against staphylococcal superantigens and other staphylococcal proteins as well as against 
inhalant allergens have been found in the nasal tissues of CRSwNP patients; Th2 cytokines are also 
highly expressed in this subgroup of patients. In addition, IgE antibodies directed against 
staphylococcal superantigens have been found in the nasal tissues of CRSwNP patients6. Recently, 
humanized antibodies such as omalizumab (anti-IgE), reslizumab and mepolizumab (anti-IL-5), as 
well as dupilumab (anti-IL-4/13) open new perspectives, and these are currently evaluated in clinical 
studies7-9. Th2 associated mediators and IgE antibodies are targets for these humanized antibodies 
in CRSwNP.   
Innate lymphoid cells in CRS. A progress in the field of immunology is that a novel family of 
CD45 expressing haematopoietic effector cells has been identified. These cells have important 
effector and regulation functions in the innate immune defense and remodeling of tissue but lack 
rearranged antigen specific surface receptors of adaptive immune cells and are therefore called 
innate lymphoid cells (ILCs)10. ILCs are classified into three categories based on the characteristic 
patterns of the cytokines they produce and the transcription factors that are necessary for their 
development and function analogous to the T helper cells: Group 1 ILCs (ILC1) produce interferon 
γ and are dependent on the transcription factor T-box expressed in T cells (T-bet), while group 2 
ILCs (ILC2) can produce Th2 cytokines such as IL-5 and IL-13 and need the transcription factor 
GATA binding protein 3 (GATA3). Group 3 ILCs (ILC3) also comprise lymphatic tissue inducing 
cells. ILC3s can produce IL-17 and/or IL-22 and require RAR-related orphan receptor gamma 
(RORγt) as transcription factor10. In this regard, ILCs are very similar to T helper cells, however, 
they are part of the innate immune defense and according to the current knowledge, they likely form 
the link between epithelium and T cell compartment11. Chemoattractant receptor homologous 
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molecule expressed on Th2 cells (CRTH2) and ST2L (IL-33 receptor) positive ILC2s have been 
detected in healthy human lungs; however, it is currently unclear which functions ILC2s have in 
humans in comparison to Th2 effector cells (that both produce IL-5 and IL-13) in the context of 
pulmonary hemostasis. Also, CRTH2+ILC2s have been identified in CRSwNP tissue12. TSLP, an 
ILC2 activators produced by epithelial cells, was increased in epithelial cells in patients with severe 
asthma13 or CRSwNP14. Only little is known about the function of other ILC subgroups in the 
airways. 
T helper cell pattern of CRS. CRSsNP appears as an only moderate, mainly neutrophil Th1 or 
Th17 polarized inflammation; CRSwNP is characterized by a moderate to high eosinophilic Th2 
polarized inflammation besides a neutrophil component, at least in Caucasians15. Presumably, the 
reduced TGF-β expression in the CRSwNP tissue contributes to a deficit of Tregs16. The relative 
deficit of Tregs could be the reason for the inability to suppress the eosinophilic inflammation in 
CRSwNP patients. In Caucasians, more than 80% of the polyps express a Th2 profile with clear 
expression of interleukin-5 protein and consecutive tissue eosinophilia whereas this profile is found 
in less than 20% of all central Chinese CRSwNP patients. Instead, there are Th17 cells that induce 
a mainly neutrophil inflammation reaction17.  
Microbiome and CRS. The nasopharynx is regarded as a considerable reservoir for bacteria in our 
body. With the advent of the field of molecular biology, culture independent methods have been 
developed in order to examine microorganisms based on their genetic patterns. As a consequence 
of this, a more complex flora was discovered in the upper airways than had previously been 
suspected. The rate of picornavirus, human respiratory syncytial virus, influenza virus, and 
parainfluenza viruses was significantly increased in CRS patients compared with that seen in the 
controls18. Frequently occurring germs of bacterial infections of CRS patients with asthma are germs 
like Staphylococcus aureus, Hemophilus influenza, Pseudomonas aeruginosa, and Moraxella 
catharralis19. Today it is well known that the nasal mucosa is always, at any time in life, colonized 
with hundreds of different bacteria that – as far as their presence is balanced – guarantee a healthy 
condition. However, the disturbed balance of the microbiome in Th1, Th2, and Th17 biased 
responses may determine the course and speed of disease development. Of interest, knowing the 
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role of microbes present in nasal tissue on the balance may help us understand the pathomechanical 
principles of CRS.  
  The aims of the studies described in this thesis are to investigate the role of S. aureus and herpes 
simplex virus 1(HSV1) in Th2 biased CRSwNP disease. For this purpose, we took advantage of our 
nasal ex vivo infection model. We exposed the CRSwNP tissue with S. aureus and HSV1, and then 
evaluated the post-infection immune response. Furthermore, the ways to restore the balance and 
inhibit the Th2 response in CRSwNP tissue was investigated.  
 
Specific aims of this thesis are: 
1) To investigate the role of S. aureus in the induction of the Th2 response in CRSwNP tissue. We 
exposed human nasal tissue cubes to S. aureus for 2h, and then placed tissue cube at air-liquid 
conditions. We aimed to unravel whether S. aureus without enterotoxin secretion can induce Th2 
cytokines and the mechanisms involved in this process. Therefore, we measured Th2 cytokines and 
epithelial cell derived cytokines at mRNA level and protein level (Chapter 3).  
2) To study whether HSV1 also affect Th2 cytokine release in CRSwNP disease. Human nasal tissue 
cubes were infected by viruses HSV1 for 1h, and then placed at air-liquid conditions. We measured 
Th1, Th2, and Th17 associated cytokines in supernatants of human nasal the ex vivo HSV1 infection 
model. We also used virus titers and immunofluorescence staining to compare the difference of 
HSV1 invasion in CRSwNP tissue and health tissue (Chapter 4) 
3) To explore the ways to inhibit the Th2 response in CRSwNP tissue. We switched off the 
expression of SOCS3 in human airway mucosa, and over-expressed SOCS3 in PANC-1 cell to 
monitor the increased expression of Foxp3. In addition, we also evaluated Th2 cytokine expressions 
after Foxp3 was up-regulated in CRSwNP tissue (Chapter 5). 
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STAPHYLOCOCCUS AUREUS INDUCES TYPE 2 CYTOKINES VIA 
TSLP AND IL-33 RELEASE IN HUMAN AIRWAY MUCOSA 
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Staphyloccoccus aureus induces type 2 cytokines via TSLP and IL-33 release in human 
airway mucosa 
Feng Lan, Nan Zhang, Gabriele Holtappels, Natalie De Ruyck, Olga Krysko, Koen Van 
Crombruggen, Harald Braun, Sebastian L. Johnston, Nikos G Papadopoulos, Claus Bachert, 
Abstract： 
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a T helper 
cell (Th)2-skewed upper airway inflammation. Mucosal Staphylococcus aureus (S. aureus) 
colonization is found in the majority of CRSwNP patients. S. aureus may induce type 2 cytokine 
release via superantigens. Additionally, we speculated that S. aureus without the ability to secrete 
enterotoxins may release epithelial cell-derived cytokines critical in propagating a type 2 immune 
response.  
Methods: Thymic stromal lymphopoietin (TSLP) and IL-33 and consecutive type 2 cytokines were 
assessed in a human mucosal tissue model upon S. aureus infection.  
Results: S. aureus infection upregulated active forms of IL-33 and TSLP, and IL-5 and IL-13 
expression in CRSwNP tissue, accompanied by elevated expressions of TSLP and IL-33 receptors, 
which were predominantly expressed on CD3+ T cells. Healthy inferior turbinate (IT) tissue after S. 
aureus infection released TSLP, but not IL-5, and Staphylococcus epidermidis did not induce any 
epithelial cell-derived cytokine release in CRSwNP or healthy IT tissue. Increased levels of IL-33 
and TSLP were also induced by S. aureus in BEAS-2B epithelial cells, accompanied by an 
activation of nuclear factor-κappaB (NF-κB) pathways. Blocking toll like receptor 2 (TLR2) using 
a specific antagonist CU-CPT22 significantly reduced the release of TSLP and IL-33 and the 
activity of NF-κB signal in BEAS-2B cells with S. aureus infection.  
Conclusions: We here demonstrate for the first time that S. aureus can directly induce epithelial 
cell-derived cytokine release via binding to TLR2, consecutively propagating type 2 cytokine 
expression in CRSwNP tissue. 
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Introduction 
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition in the 
upper airways which is often accompanied by co-morbid asthma. A smaller population of Chinese 
CRSwNP patients, but 85% of European CRSwNP patients show T helper cell (Th) 2-biased and 
eosinophilic inflammation1-5. An increase in colonization with Staphylococcus aureus (S. aureus) 
and the presence of S. aureus enterotoxin-specific Immunoglobulin E (IgE) antibodies have been 
demonstrated in the mucosa of CRSwNP subjects in comparison with control or chronic 
rhinosinusitis without nasal polyps (CRSsNP) patients6, 7, being even higher in CRSwNP patients 
with asthma comorbidity and aspirin sensitivity. Critically, staphylococcal enterotoxin B (SEB) of 
S. aureus induces considerable release of pro-inflammatory and Th2-associated cytokines including 
IL-4, IL-5 and IL-13 and also enhances eosinophilic inflammation in human nasal and in mouse 
bronchial tissue8-11. However, a link between S. aureus biofilms and skewing of the Th2 response 
has also been demonstrated independent from enterotoxin activities12. Thus S. aureus may impact 
on Th2 responses not only via enterotoxins; those pathomechanisms await discovery. 
Epithelial cells act as the first physical defense barrier. Cytokines derived from epithelial cells 
such as IL-33 and thymic stromal lymphopoietin (TSLP), potentially released by various viral and 
bacterial stimuli, are critical in orchestrating innate immune responses, specifically a Th2 immune 
response. IL-33 has been implicated in asthma, and pretreatment of a mouse model of asthma with 
anti-IL-33 antibodies result in a decrease of serum IgE, eosinophils and concentrations of IL-4, IL-
5 and IL-13 in broncho-alveolar lavage fluid. Similar to IL-33, TSLP also can affect Th2-type 
airway inflammation by trigging dendritic cells13. Recently, Nagarkar et al. have successfully shown 
that truncated TSLP with biological activity is increased in CRSwNP, enhancing IL-5 production 
from mast cells14. Besides the classical Th2 cells, a new group of innate lymphoid cells (ILC2s) also 
can produce type 2 cytokines including IL-5, IL-9 and IL-13 in response to IL-25 and IL-3315. These 
evidences identify a close relationship between epithelial cell derived cytokines and type 2 skewed 
airway diseases. 
Importantly, TSLP can be induced by rhinovirus or double stranded RNA as a surrogate for viral 
RNA in human airway epithelial cells16. IL-33 was related to virus-induced asthma exacerbation 
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severity and rhinovirus-induced IL-33 was able to strongly induce type 2 cytokines in human T cells 
and ILC2s17. Even though increased levels of IL-33 are shown in an atopic dermatitis mouse model 
after SEB exposure18, and SEB reportedly disrupts epithelial integrity through cytotoxic effects and 
reduces epithelial tight junction expression, increasing cellular permeability in rat intestinal 
mucosa19. However, the role of S. aureus inducing type 2 immune responses independent of 
enterotoxins in human chronic airway disease via epithelial cell derived cytokines has not been 
elucidated. 
S. aureus colonization is frequently found in Th2-biased inflammation in CRSwNP patients with 
asthma comorbidity4. Making use of formerly described human nasal tissue models20, we here 
developed a human mucosal tissue S. aureus infection model to investigate the possible role of S. 
aureus in a Th2 response in chronic upper airway disease. We specifically analyzed epithelial cell 
derived cytokine release in CRSwNP tissue induced by a S. aureus strain unable to secrete classical 
enterotoxins such as SEB, and studied the subsequent type 2 cytokines expression.  
Methods 
Patients Nasal tissues were obtained from 20 CRSwNP patients and 21 control patients at the 
department of Oto-Rhino-Laryngology, Ghent University Hospital. None of the patients had taken 
oral or nasal corticosteroids for four weeks and antibiotics for two weeks before surgery. The 
diagnosis of CRSwNP was made according to the European Position Paper on Rhinosinusitis and 
Nasal polyps (EPOS) 2007 guidelines21. The inferior turbinates of patients with septal deviation  
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were used as controls. The clinical data of all the patients are shown in Table 1. Informed consent 
was obtained from all patients before sample collection. The ethics committees of the Ghent 
University Hospital approved the study.  
Table 1 Clinical data of included patients. 
AERD, Aspirin-exacerbated respiratory disease;  
 
S. aureus and S. epidermidis stocks GFP labeled S. aureus RN6390, containing the plasmid 
pALC1743, a pSK236-derived shuttle plasmid carrying an active S. aureus promoter (RNAIII 
promoter), was chosen as infection strain in this study. In particular, this strain does not produce S. 
aureus enterotoxins which had been confirmed by a lack of enterotoxin detection. Enterotoxins A, 
B, C, D were tested using SET-RPLA kit in Trypticase Soy medium (BD Belgium) after S. aureus 
overnight culture at 37°C, while toxic shock syndrome toxin 1 was assayed using (TST-RPLA KT) 
(both from Oxoid, Hampshire, UK). To investigate the specific role of S. aureus, Staphylococcus 
epidermidis (S. epidermidis) (ATCC 14990) was also used in infection model. A concentration of 
bacteria 20×106 CFU/well was prepared and used according to previous experiments20. 
Human airway infection model CRSwNP tissue or control tissue were cut into small cubes 
approximately 25 mm2 in size and washed three times by TCM with antibiotics (50 IU/mL penicillin) 
(Invitrogen, Belgium) and 50 µg/mL streptomycin (Invitrogen). Then tissue cubes were placed on 
 Chronic rhinosinusitis with nasal 
polyps (CRSwNP) subjects   
Control subjects  
No. of subjects 20 21 
Age, median (range) 47.8(30-65) 31.2 (15-58) 
Gender female/male 9/11 10/11 
Atopy 7/20 3/21 
Asthma 13/20 0/21 
AERD 5/20 0/21 
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a triangle metal mesh in a 6-well plate at air liquid interface conditions at 37°C in humidified air 
with 5% CO2 over-night. After 2h of S. aureus or S. epidermidis infection, all tissue cubes were 
transferred on triangle metal mesh again in a 6-well plate for another 24h or 48h incubation. The 
tissue cubes in tissue culture medium alone were taken as control group. Human bronchial epithelial 
cell line BEAS-2B cells (5x104 cells/well) were placed in a 24-well plate at 37°C in 5% CO2 
overnight. When reaching 70%-80% confluence, BEAS-2B cells were stimulated by S. aureus or S. 
epidermidis for 15min at different concentrations from 106 to 102cfu/ml, and were washed 2 times 
by PBS for another 10h or 24h incubation. A concentration of bacteria of 106 cfu/ml and the 10h 
incubation time were suitable for further epithelial derived cytokine pathway investigations in terms 
of induction of cell death, TSLP and IL-33 cytokine release. To block TSLP and IL-33 releases 
from BEAS-2B cell after S. aureus infection, cells were pretreated with the novel Toll like receptor 
(TLR)2 antagonist CUCPT22 (Tocris Bioscience, Ellisville, MO) for 1h, followed by S. aureus 
infection. Experiments were repeated four times. The supernatant and the protein of cells were 
collected for further study. 
Stimulation of nasal single cell suspension Single cell suspensions of human CRSwNP mucosa 
were prepared as described22. 5x106 human nasal single cells per well were stimulated with 
recombinant human (rh) TSLP, rhIL-33 and both cytokines together (R&D, Minneapolis) with 
different doses for 24h. Finally, recombinant TSLP and IL-33 were used at a concentration of 
100ng/ml for the induction of IL-5 release. After 24h incubation, cytokines were measured in the 
supernatants of single cell suspensions.  
qRT-PCR After extraction of total RNA by using the RNeasy kit (QIAGEN GmbH, Hilden, 
Germany), 5 ng cDNA was synthesized by using the iScript Advanced cDNA-synthesis Kit (BioRad 
laboratories, CA, USA). The target product was detected by Sso Advanced SYBR Green Super mix 
(BioRad) on the LightCycler 480 Instrument II (Roche Applied Science, Penzberg, Germany) using 
the primer sequences as shown in Table 2. To normalize for transcription and amplification 
variations among the samples, two housekeeping genes were used: Succinate Dehydrogenase 
Complex and elongation factor 1. The relative quantities expressed were calculated with the 
commercially available qBasePlus software (BioRad)23.  
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Table 2 The primers sequence used for qRT-PCR. 
Cytokine measurements Cytokine measurements were performed in BEAS-2B cells as well as in 
supernatants or tissue homogenates of tissue from human airway infection model. Tissue 
homogenates were prepared as described earlier24. IL-4, IL-5, and IL-13 measurements were 
assayed by using Luminex xMAP suspension array technology in a Bio-Plex 200 system (BioRad, 
MI). Kits for total TSLP and IL-33 measurement were purchased from R&D Company. All cytokine 
measurements were expressed as pg/ml. Cytokine measurement in supernatants of tissue from 
human mucosal tissue S. aureus infection model was calibrated by tissue cube weight. 
Immunofluorescence staining The CRSwNP tissue from infection model was embedded using 
frozen tissue medium (Klinipath, Duiven, the Netherlands). Sections were incubated with IL-33 
antibody from R&D (7.5µg/ml) to evaluate the expression of IL-33 in CRSwNP tissue with 
infection. Additionally, to determine the location of the TSLP receptor (TSLPR) and IL-33 receptor 
Targets Forward (5’-3’) Reverse (5’-3’) Amplicon 
size (bp) 
Accession 
number 
IL-33 TGAATCAGGTGAC
GGTGTTGATGG 
TGAAGGACAAAGAAGGCC
TGGTC 
150 NM_033439.3 
TSLP ACTTGCCAACAGG
TAAGAGGA AGC 
AGGCTTGTTCCACAGTAAG
TGCTC 
77 NM_033035.4 
IL-25 AGTCCTGTAGGGC
CAGTGAAGATG 
CCGGTTCAAGTCTCTGTCC
AACTC 
86 NM_022789.3 
IL-5 AACTCTGCTGATA
GCCAATGAGAC 
ACTCTCCAGTGTGCCTATT
CCC 
106 NM_000879.2 
IL-4 ACAGCCTCACAGA
GCAGAAGAC 
TCTCATGGTGGCTGTAGAA
CTGC 
138  NM_000589.3 
IL-13 CAACATCACCCAG
AACCAGAAGGC 
AGGTTGATGCTCCATACCA
TGCTG 
63 NM_002188.2 
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long form ST2 receptor (ST2L), double staining was performed on cryosections by incubation with 
7.5µg/ml TSLPR antibody (R&D) and CD3 monoclonal antibody (clone F7.2.38; 1:50; DAKO, 
Trappes, France), or 7.5µg/ml ST2L (R&D) antibody and CD3 for 2h at room temperature. At the 
end of this incubation, the sections were mounted with glycerin-DABCO (Janssen Chemica, Beerse, 
Belgium). Images were obtained using a Leica TCS SPE laser scanning spectral confocal system 
linked to a DM B fluorescence microscope (Leica Microsystems). Leica confocal software was used 
for image acquisition. 
Western blotting  
Total protein was extracted from CRSwNP tissue and BEAS-2B cells after S. aureus infection using 
the RAPI buffer (Invitrogen) with cocktail proteinase inhibitor (Roche). The following antibodies 
were used for western blotting: anti-P50 (1:700), anti-phospho-P50 (Tyr705) (1:700), anti-P65 
(1:800), anti-phospho-P65 (Tyr694) (1:600), anti-IL-33 (0.2µg/ml), anti-TSLP (0.1µg/ml), anti-
TSLPR (1µg/ml) and anti-ST2L (0.1 µg/ml). All antibodies were from Cell Signaling Technology 
(Cambridge, UK) except anti-P50, anti-phospho-P50, anti-TSLPR, anti-ST2L antibody, and HRP-
conjugated secondary antibody (1:6000). Anti-P50, anti-phospho-P50, HRP-conjugated secondary 
antibodies were from Santa Cruz (Santa Cruz, CA); anti-IL-33, anti-TSLP, anti-TSLPR and anti-
ST2L antibodies were from R&D. IL-33 and TSLP were detected using Tris-Tricine gel, while the 
other proteins described in the manuscript were measured using Tris-glycine gel. The relative band 
densities of the target protein to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Invitrogen, 
Belgium) were estimated by Lab image Analysis Software (Bio-Rad, CA). 
Flow cytometry CRSwNP tissue cubes with S. aureus infection 24h (n=3 in quadruplicate) were 
collected for single cell suspensions as described above. To measure the expression of TSLPR, the 
single cells were stained with anti-CD3-Vioblue anti-TSLPR-APC antibodies for 30 min. The IL-
33 receptor ST2L is internalized after binding to IL-33, reducing IL-33-induced cytokine release25. 
Thus, following 30min anti-CD3-Vioblue incubation, single cells from S. aureus infection model 
were intracellularly stained by anti-ST2L-PE (R&D) after fixation and permeabilization. Data was 
acquired on a BD FACS Canto II using FACS Diva software (BD Bioscience) and FlowJo software 
(Tree Star Inc., Ashland, OR) for analysis. 
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Statistical analyses The data were analyzed using graphpad prism software (GraphPad Software, 
san Diego, CA). Statistical analysis was performed by using the Wilcoxon test for paired 
comparisons. Data comparison within different groups was performed using the Kruskal-Wallis test. 
A p value < .05 was considered statistically significant. 
Results 
Active forms of TSLP and IL-33 were induced in CRSwNP tissue in the presence of S. aureus, 
but not S. epidermidis. Two human transcript variants of TSLP were described; RT-PCR analysis 
demonstrated that the mRNA level of lfTSLP, an active form of TSLP, increased in CRSwNP tissue 
and healthy control tissue 24h after S. aureus infection; in contrast, the expression of sfTSLP, 
possessing antibacterial property, decreased in CRSwNP and healthy control tissue 24h and 48h 
after S. aureus infection (Figure 1A). The level of TSLP protein was significantly higher in the 
supernatants of CRSwNP and healthy control tissue after 48h exposure to S. aureus than that in the 
supernatants of unexposed tissue (Figure 1B). IL-33 mRNA in CRSwNP and healthy control tissue 
did not significantly increase due to S. aureus incubation (Figure 1A). However, IL-33 protein was 
increased in CRSwNP tissue homogenates, but not in control tissue, 24h after S. aureus infection 
(Figure 1B). The ELISA measurements of TSLP and IL-33 did not distinguish different variants. 
Therefore, full length IL-33, processed IL-33 (active form) and long-form TSLP were studied after 
separation in Tris-Tricine gel in the CRSwNP tissue after S. aureus exposure (Figure1C). 
Recombinant, N terminally truncated human IL-33 proteins, human lfTSLP and sfTSLP were used 
as controls. Understanding the location of IL-33 in S. aureus infected tissue also helps to evaluate 
its functional status; therefore IL-33 immunofluorescence staining was performed. A high amount 
of IL-33 was observed in the extracellular space between epithelial cells of CRSwNP after S. aureus 
stimulation for 24h (Figure 1D).  
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Figure 1. Epithelial cell derived cytokines TSLP and IL-33 were induced in CRSwNP tissue in the 
presence of S. aureus. (A)Gene expressions of long form TSLP (lfTSLP), short form TSLP (sfTSLP) 
and IL-33 in CRSwNP (n=7) and healthy inferior turbinate (IT) tissues (n=8) with staphylococcus aureus 
(S. aureus) infection for 24h or 48h. Tissue cubes in tissue culture medium (TCM) were taken as controls 
(*P<.05). (B) The protein level of TSLP and IL-33 CRSwNP and IT tissues with S. aureus infection for 
24h or 48h (*P<.05). (C) Full-length IL-33, active IL-33, long form TSLP and short form TSLP were 
identify by Tris-Tricine gel. (D) IL-33 was observed in the extracellular space of epithelial cells in 
CRSwNP tissue with S. aureus infection for 24h. Low expression of IL-33 was found in control 
conditions without any infection. (All slides viewed at 630x magnifications; pink fluorescence 
demonstrates the presence of IL-33 and green fluorescence the presence of S. aureus (SA) in the nasal 
mucosa; isotype control staining for IL-33 was completely negative (not presented here)). 
S. epidermidis, the same staphylococcus genus of S. aureus, was used in the human mucosal 
tissue infection model as a control to demonstrate specificity of the effect of S. aureus on epithelial 
cell-derived cytokine release. S. epidermidis did not induce TSLP nor IL-33 proteins in both the 
CRSwNP tissues (Figure 2A). A low basal epithelial expression of IL-33 without any release could 
be found in CRSwNP tissue after 24h S. epidermidis infection (Figure 2B), suggesting that 
specifically S. aureus infection, but not S. epidermidis induced IL-33 release in CRSwNP tissue.  
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Figure 2. The expression of epithelial cell derived cytokines in CRSwNP tissue after Staphylococcus 
epidermidis (S. epidermidis) infection. (A) Protein levels of TSLP and IL-33 were measured in 
CRSwNP tissue with S. epidermidis infection 24 or 48h (n=3). (B) The immunofluorsence staining of 
IL-33 expression in CRSwNP tissue with S. epidermidis infection for 24h. Tissue cubes with tissue 
culture medium (TCM) were taken as controls. (All pictures viewed at 630x magnifications. Blue 
fluorescence indicates the nuclear of cell, and pink fluorescence stands for the location of IL-33.)  
CD3+TSLPR+ and CD3+ST2L+ cells increased in CRSwNP tissue after S. aureus infection. To 
further unveil TSLP and IL-33 signaling pathways in the human airway infection model, expression 
and localization of TSLPR and ST2L upon S. aureus exposure were evaluated by 
immunofluorescence staining, western blot and flow cytometry. Increased levels of TSLPR and 
ST2L were observed in the epithelial layer of CRSwNP mucosa after 24h (Figure 3A-B). The 
majority of TSLPR and ST2L was expressed on CD3+ T cells in the epithelial and sub-epithelial 
layers. In line with the staining results, the expression of TSLPR and ST2L proteins were 
significantly up-regulated 48h after S. aureus infection in comparison with non-infected mucosal 
tissue using western blot assay (Figure 3C-D). Additionally, the number of CD3+ST2L+ and 
CD3+TSLPR+ cells in tissue increased in response to S. aureus exposure (Figure 3E). ST2L and 
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TSLPR were expressed on CD3- T cells, whereas the number of CD3-ST2L+and CD3-TSLPR+ cells 
increased marginally only after S. aureus infection (Figure 3F).   
 
Figure 3. TSLPR and ST2L positive T cells increased in CRSwNP tissue after S. aureus infection. 
(A-B) Immunofluorescence staining pictures of TSLP receptor (TSLPR)+CD3+cells (white arrow) and 
IL-33 receptor (ST2L)+CD3+ cells (white arrow) in CRSwNP tissue with Staphylococcus aureus (S. 
aureus) infection for 24h. CRSwNP tissue cubes with tissue culture medium (TCM) were taken as 
controls (All slides viewed at 630x magnification; yellow fluorescence demonstrated the presence of 
receptors and red fluorescence stood for the presence of CD3+ cell in the nasal mucosa; isotype control 
staining for TSLPR and ST2L was completely negative (not presented here)). (C) Western blot pictures 
of TSLPR and ST2L in CRSwNP tissue with S. aureus infection for 24h. (D) Quantification for TSLPR 
and ST2L proteins in CRSwNP tissues with S. aureus (SA) infection (*P<.05). (E) The expressions of 
TSLPR+CD3+ and ST2L+CD3+ cells were identified in CRSwNP tissue with S. aureus infection (n=3). 
(F) The expressions of TSLPR+CD3- and ST2L+CD3- cells were identified in CRSwNP tissue with S. 
aureus infection (n=3).  
A Th2 response is induced in CRSwNP tissue, but not in healthy control tissue, in the presence 
of S. aureus. To determine the contribution of TSLP and IL-33 to type 2 cytokine release in the 
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human airway infection model, IL-4, IL-5, IL-13 were measured. IL-5 and IL-13 mRNA expression 
and IL-5 protein release were up-regulated in CRSwNP tissue 48h after S. aureus infection, but not 
in control tissue (Figure 4A). Human nasal single cell suspensions of CRSwNP patients were 
stimulated with rhTSLP and rhIL-33, both individually and together. IL-5 can be induced from 
single cell suspensions in the presence of rhTSLP or rhIL-33 alone (Figure 4B). Analysis of IL-5 
expression in single cell suspensions after combined rhTSLP and rhIL-33 stimulation demonstrated 
a further significant increase over rhTSLP alone and rhIL-33 alone (Figure 4B).  
 
 
 
 
 
 
Figure 4. Th2 response is induced in CRSwNP tissue in the presence of S. aureus. (A) The expression 
of IL-4, IL-5 and IL-13 in CRSwNP and healthy inferior turbinate (IT) tissues with Staphylococcus 
aureus (S. aureus) infection for 24h or 48h. Tissue cubes with tissue culture medium (TCM) were taken 
as controls (*P<.05). (B) IL-5 cytokine increased in single cell suspensions with rhTSLP and rhIL-33 
stimulation for 24h (*P <.05). 
S. aureus induced release of IL-33 and TSLP partially via Toll-like receptor 2. To further 
confirm what had been observed in the human mucosal tissue infection model, epithelial BEAS-2B 
cells were infected with S. aureus. In BEAS-2B cells, we confirmed that S. aureus induced TSLP 
and IL-33 release in a dose-dependent fashion (Figure 5A). The relevant NF-κB signaling pathways 
were investigated to analyze epithelial cell derived cytokine production mechanisms in BEAS-2B 
cells. Activation of the NF-κB pathway in epithelial cells was evident from an increase in 
phosphorylation of P50 and P65 at early time points in BEAS-2B cell after S. aureus exposure 
(Figure 5A). In contrast, no induction of TSLP or IL-33 expression (data not shown) or up-
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regulation of the NF-κB in BEAS-2B cells was observed after S. epidermidis infection (data not 
shown). The result demonstrated that the novel TLR2 antagonist CUCPT22 inhibited the 
phosphorylation of P50 and P65 in BEAS-2B cell 10h after S. aureus infection. Consequently, the 
downstream IL-33 and TSLP expressions decreased in BEAS-2B cells in a dose-dependent manner 
(Figure 5B). 
 
Figure 5. Expression of TSLP and IL-33 in supernatants of the bronchial epithelial cell line BEAS-
2B after S. aureus infection; possible induction pathway. (A) a, TSLP and IL-33 expression in 
supernatants of bronchial epithelial cell line BEAS-2B cells after exposure to different concentrations of 
Staphylococcus aureus (S. aureus) for 10h. b, Correlation of time-dependent increase in P50 and P65 
phosphorylation in BEAS-2B cells with S. aureus infection. SA means S. aureus (*P <.05) (B) Novel 
toll like receptor 2 (TLR2) antagonist CU-CPT22 partially inhibited the phosphorylation of P50 and P65 
and their downstream of IL-33 and TSLP expression in BEAS-2B cells 10h after S. aureus infection. (*P 
<.05) 
 
Discussion 
We demonstrate for the first time that S. aureus can directly induce the release of the active forms 
of epithelial cell-derived cytokines TSLP and IL-33 from human nasal tissue, accompanied by the 
up-regulation of CD3+TSLPR+ and CD3+ST2L+ cells, IL-5 and IL-13 mRNA expression and IL-5 
protein release in CRSwNP, but not in control tissue. NF-κB signaling is involved in the production 
of TSLP and IL-33 after binding of S. aureus to TLR2; S. epidermidis infection did not induce any 
cytokines.   
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  The tissue explants here serve as a bridge between cell culture and in vivo environment. In this 
study, we infected nasal tissue explants, instead of cell lines or primary cells, with S. aureus to 
efficiently reflect the in-vivo situation in the nose after infection. We also focused on the role of S. 
aureus itself, not the extractions from S. aureus or toxins produced by S. aureus, in Th2 biased 
upper airways disease. As demonstrated earlier, enterotoxins are known to work as superantigens 
and induce high amounts of Th2 cytokines and induce IgE formation in CRSwNP tissue26; CD4+ T 
cells from BALB/c mouse with subcutaneous footpad S. aureus infection produce a high amount of 
Th2 cytokines like IL-4 and IL-1327. In this study, we successfully demonstrated that a S. aureus 
strain without enterotoxin secretion can directly induce IL-5 and IL-13 in CRSwNP tissue, but not 
IL-4, via the epithelial cytokines IL-33 and TSLP. Our data also unveiled that type 2 cytokines can 
only be induced by S. aureus, not by S. epidermidis in CRSwNP tissue. The downstream activities 
of epithelial cell derived cytokines are well studied, whereas the factors that affect epithelial cell-
derived cytokine release are only partially known. Rhinovirus exposure appears to trigger TSLP 
expression in the lung of mice with allergic airway inflammation28. Mouse epithelial cells MLE-15 
and human alveolar epithelial cells A549 infected with influenza virus result in IL-33 release29. 
TSLP is produced by murine dendritic cells in response to certain microbial pathogen products such 
as lipopolysaccharide, flagellin, FLS-1 and pam3csk430. S. aureus membrane and diacylated 
lipopeptides can induce TSLP release in human keratinocytes31. Heat inactivated S. aureus infection 
increases IL-33 in human and murine epidermal keratinocytes and murine dermal macrophages32. 
However, there was no understanding of the relationship between S. aureus germs and epithelial 
cell-derived cytokines or Th2 responses in human. We formerly demonstrated that staphylococcal 
enterotoxins can induce Th2 cytokines, but also Th1 and Th17 related cytokines, in nasal healthy 
and CRSwNP tissue26. Here we show that enterotoxin non-producing S. aureus can induce both 
TSLP and IL-33 release in human CRSwNP tissue and human bronchial epithelial cells. Even 
though the predominant form of TSLP remains controversial in humans, two different TSLP forms 
have been described: lfTSLP is understood as the functional human TSLP33; whereas human sfTSLP 
exhibits a marked antibacterial activity in skin and salivary glands34. We demonstrate that lfTSLP 
increased at mRNA and protein level in CRSwNP tissue with S. aureus infection with the potential 
to propagate Th2 immune responses; while sfTSLP decreased in CRSwNP with S. aureus infection, 
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further decreasing the mucosal defense. IL-33 is a chromatin-associated nuclear cytokine from the 
IL-1 family that functions as an ‘‘alarmin’’. It has been shown to be constitutively expressed in the 
nuclei of epithelial cells35 and to be released into the extracellular space after cell necrosis36 to elicit 
innate immune responses. Recently, it has been reported that the biological activity of full-length 
IL-33 is increased by neutrophil elastase and cathepsin G37,38. Based on our immunofluorescence 
staining, a high amount of IL-33 was observed in the extracellular space between epithelial cells, 
which was in accordance with increased CRSwNP tissue homogenate protein levels of IL-33 after 
S. aureus infection for 24h. In contrast, IL-33 preferentially was located in the nuclei of nasal basal 
cells in CRSwNP tissue without stimulation, or after S. epidermidis exposure, not impacting on the 
mucosal immune response. Additionally, full-length IL-33 and processed IL-33 were observed in 
CRSwNP tissue with S. aureus infection, indicating that induced IL-33 in the nasal infection model 
is functional. 
Besides the release of TSLP and IL-33, S. aureus infection also can increase the expression of 
their receptors. The increased TSLPR and ST2L receptors were mainly expressed on CD3+ T cells 
in CRSwNP tissue, reinforcing the signals. Thus, CD3+T cells here are likely to contribute to the 
IL-5 production after infection. This does not exclude the contribution of ILC2 cell and mast cell, 
even though the number of CD3-TSLPR+ and CD3-ST2L+ increased only marginally after infection. 
Interestingly, a consequent IL-5 protein release was propagated in CRSwNP tissue, but not in 
control tissue, upon infection; this could be related to the typical Th2 bias in CRSwNP with 
increased numbers of activated Th2 cells present. Furthermore, defense mechanisms against S. 
aureus may be impaired in CRSwNP, with a high rate of alternatively activated macrophages in 
CRSwNP vs. healthy mucosa, not suited to phagocytize and kill S. aureus efficiently39. This 
consecutively may lead to a continuous stimulation of the mucosal tissue in CRSwNP patients by S. 
aureus contributing to the persistence of inflammation.  
It remains to be studied whether S. aureus can amplify preexisting type 2 airway inflammation 
only, or initiate it. Furthermore, the role of IL-25 in this situation needs further focus; S. aureus 
exposure induced IL-25 protein in BEAS-2B cells (data not shown), but not in the mucosal tissue 
models.  
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  In summary, we here highlight for the first time that S. aureus, but not S. epidermidis, induces 
the release of type 2 cytokines in CRSwNP tissue via epithelial derived cytokines TSLP and IL-33. 
TLR2 and NF-κB signal are involved in the production of TSLP and IL-33 after S. aureus exposure. 
With the known high colonization of CRSwNP tissue by S. aureus, this likely contributes to the 
initiation or persistence of the Th2-biased inflammation in this disease. 
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CHAPTER 4 
 
TH2 BIASED UPPER AIRWAY INFLAMMTION IS ASSOCIATED WITH AN IMPARIED 
RESPONSE TO VIRUAL INFECTION WITH HERPES SIMPLEX VIRUS 1 
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Th2 biased upper airway inflammation is associated with an impaired response to viral infection 
with Herpes simplex virus 1 
Feng Lan, Xiangdong Wang, Hans J Nauwynck, Gabriele Holtappels, Luo Zhang, 
Sebastian L Johnston, Nikolaos G, Papadopoulos, Claus Bachert, Nan Zhang 
Rhinology (accepted) 
Abstract 
Background: We aimed to elucidate possible differences in antiviral defense in chronic 
rhinosinusitis with nasal polyps (CRSwNP) mucosal tissue compared to healthy mucosal tissue 
(HMT) upon herpes simplex virus 1 (HSV1) exposure.  
Material and methods: HMT and CRSwNP samples were infected with HSV1. We visualized the 
virus location by immunofluorescence and monitored invasion by a score. The mediators Interferon 
(IFN)-α, IFN-β, IFN-λ, IFN-γ, Interleukin (IL)-6, IL-1β, Tumor necrosis factor (TNF)-α, IL-17, IL-
5, IL-10 were measured in culture supernatants at baseline and at 24h, 48h and 72h after virus 
incubation.  
Results: CRSwNP mucosal tissue showed a significant deficit in IFN-γ and IL-17 release within 24 
to 72h after infection in comparison to HMT, at the same time releasing significantly more pro-
inflammatory cytokines including IL-1β and TNF. These findings were associated with 
significantly higher viral invasion scores at 48 and 72h in CRSwNP mucosa compared to those for 
the HMT. 
Conclusions: We demonstrate for the first time in a human ex-vivo mucosal model that the 
inadequate response of CRSwNP may be associated with a deeper intrusion of viruses into the 
mucosal tissue, and may contribute to more and longer symptoms upon acute infection, but also to 
the persistence of inflammation in CRSwNP tissue. 
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Introduction: 
Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a preferentially eosinophilic type of 
inflammation of the upper airways, characterized by the overproduction of IL-5, eosinophil-cationic 
protein (ECP) and immunoglobulin (Ig)E; CRSwNP also is frequently associated with comorbid 
asthma1. Viral infections are known as the most frequent cause of acute rhinitis and may cause 
asthma exacerbations in children and adults, with human rhinoviruses being identified as the most 
prominent, but not exclusive agent2-4. Although natural and experimental rhinovirus infections have 
been studied extensively with respect to clinical manifestation and pathophysiological responses in 
healthy subjects5, 6, little is known about viral infections in patients with chronic inflammatory 
disease of the nose and sinuses such as CRSwNP.  
Herpes simplex virus 1 (HSV1) infections are highly prevalent in humans. HSV1 is characterized 
by a comparatively high global sero-prevalence with rates of infection between 65% and 90% 
worldwide7-9. Although people infected with HSV often develop labial or genital lesions, the 
majority are either undiagnosed or display no physical symptoms; individuals with no symptoms 
are described as asymptomatic or as having subclinical herpes. Findings from a recent study have 
shown that 8% (2/23) of human nasal polyps may be infected with HSV1 at a given moment in time; 
although this seems a low incidence, it underlines the possible role of HSV1 in upper airway 
disease10. Furthermore, HSV infection is a risk factor for nasal carriage of Staphylococcus aureus 
(S. aureus) in human immunodeficiency virus -infected patients11. For herpes virus infection in 
animals, the nasal mucosa is considered the primary site of replication12.  
It was recently shown that the response to viral infections (rhinovirus) is also impaired in 
asthmatics vs. healthy controls, with a deficit in the mucosal production and release of interferons 
in response to the viral challenge, which may impair the mucosal defense and allow the virus to 
replicate at a high rate13. The mucosa in asthmatics is characterized by a Th2 bias, similar to the 
situation in CRSwNP. In the current study we therefore aimed to study the cytokine response related 
to a viral agent, HSV1, in our CRSwNP whole mucosal tissue model compared to control samples 
to elucidate possible differences in antiviral defense.   
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Materials and methods 
Nasal mucosa tissue 
Inferior turbinate healthy mucosal tissue (HMT) was obtained from 7 non-allergic patients (average 
age 36 years (range: 23-52)) scheduled for turbinate surgery due to septal deviations or turbinate 
hypertrophy without asthma and other diseases. Nasal polyp tissues were obtained from 7 patients 
with CRSwNP (average age 48.5 years (range: 17.4-68.8)) by endoscopic sinus surgery at the 
department of Oto-Rhino-Laryngology, Ghent University Hospital. The diagnosis of sinus disease 
was based on history, clinical examination, nasal endoscopy, and CT scanning of the sinuses 
according to the European Position Paper on Rhinosinusitis and Nasal Polyps14. The atopic status 
of patients was evaluated by skin prick tests with the European standard panel of 14 inhalant 
allergens. Negative and positive controls (10mg/mL histamine solution) were included with each 
skin prick tests. One CRSwNP patient had a positive skin prick test, two patients reported mild 
asthma, and one patient reported aspirin intolerance.   
The ethics committee of the Ghent University Hospital approved the study, Belgium registration 
number B670201317380; all patients were asked to refrain from oral corticosteroids or antibiotics 
4 weeks and topical corticosteroids 2 weeks preoperatively and gave their written informed consent.  
Measurement of cytokine and IgE levels in tissue homogenates 
Freshly obtained tissue specimens were homogenized, as previously described15, and assayed for 
IL-5, IFN-γ and IL-17, by using commercially available Quantikine ELISA kits (R&D Systems, 
Minneapolis, MN, USA) following the instructions of the manufacture. IgE and ECP were measured 
by using the UNICAP system (Pharmacia, Uppsala, Sweden).  
HSV1 stocks 
HSV1 (ATCC, VR-733, strain F) was purchased from the American Type Culture Collection 
(ATCC; Rockville, MD, USA) and propagated to large quantities by infection of African green 
monkey kidney (Vero) cells (ATCC CCL-81; Rockville, MD, USA). The virus strains were 
passaged twice and diluted in serum-free medium (50% RPMI medium 1640 (Invitrogen, Merelbeke, 
East Flanders, Belgium) and Dulbecco's Modified Eagle Medium (Invitrogen, Belgium), 50IU/mL 
penicillin (Invitrogen, Belgium) and 50µg/mL streptomycin (Invitrogen, Belgium) to a final 
concentration of 107 TCID50 (50% tissue culture infectious dose of a virus)/ml. Tissue culture 
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medium (TCM, contains equal amounts of RPMI medium 1640 (Invitrogen, Merelbeke, East 
Flanders, Belgium) and Dulbecco's Modified Eagle Medium (Invitrogen, Belgium)) were used for 
all subsequent experiments involving infection of nasal turbinate tissue ex-vivo.  
Culture and infection of healthy nasal turbinate and nasal polyp explants with HSV1 (Figure 
1) 
Nasal turbinate and nasal polyp tissue obtained from each patient following surgery was 
immediately washed three times with serum-free medium supplemented with antibiotics (50IU/mL 
penicillin (Invitrogen, Belgium) and 50µg/mL streptomycin (Invitrogen, Belgium) and cultured 
according to the following protocol. The washed tissue explant was cut into smaller cubes 
approximately 25mm2 in size. Nasal tissue cubes of each turbinate or nasal polyp explants were 
used for further investigation, divided into two equal groups of two cubes each (Group 1 (A,B 
wells)= HSV1 infection group; Group 2 (A, B wells)= control, non-infection group, Group 1B and 
Group 2B cubes were divided into 2 parts before any treatment ). Each cube was placed with the 
epithelial surface upwards on sterile fine-meshed gauze in a 6-well tissue-culture plate (Falcon, BD 
Biosciences, Erembodegem, East Flanders, Belgium) and 3 ml serum-free medium supplemented 
with antibiotics was added to each well to create an air-liquid interface. All tissue cubes were 
conditioned as explant cultures by incubation for 24h at 37 °C in 5% CO2 in air atmosphere, and 
then transferred to a 24-well tissue-culture plate (Falcon, BD Biosciences, Belgium). Groups 1 
tissue cubes were inoculated with 1.0 mL inoculum containing 107 TCID50 of HSV1, and 1.0mL of 
serum-free tissue culture medium (TCM) was added to the tissue cubes in Groups 2 as mock-
condition, all tissue cubes were incubated for 1h at 37 °C in 5% CO2 in air atmosphere. All tissue 
cubes were washed three times, transferred onto sterile fine-meshed gauze and incubated in a 6-well 
tissue-culture plate for either 24h or 48h under air-liquid interface culture conditions as before. At 
the end of each incubation period, the culture supernatants from Group 1A and Group 2A were 
collected, and tissue cube parts from Group 1B and Group 2B were collected, weighted  and snap-
frozen respectively at 24h or 48h time point, store at -80 °C for further evaluation. In order to 
investigate the spontaneous release, the tissue cubes which underwent 48h culture were transferred 
to a 6-well tissue-culture plate with fresh tissue culture medium for a final 24h incubation period 
(in total 72h tissue incubation) on fine-meshed gauze at an air-liquid interface. At the end of the 
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culture, the culture supernatant were collected and the tissue cubes were weighed and snap-frozen 
in liquid nitrogen and stored at -80 °C until further assessment. In the process of developing this 
model, we used uninfected vero cell lysates, heat inactivated HSV1 and tissue culture medium 
(TCM) as controls vs HSV1; as the controls showed the same morphology and cytokine response 
patterns, here we only used TCM as control. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study flow. Culture and infection of nasal turbinate healthy mucosa tissue and nasal polyp 
explants with HSV1: Nasal tissue cubes were divided into two equal groups of two cubes each (Group 1 
= HSV1 infection group; Group 2 = control, non-infection group). Group 1 tissue cubes were inoculated 
with HSV1, and serum-free medium was added to the tissue cubes in Group 2 as mock-condition. 
 
Immunofluorescence staining for evaluation of HSV1 invasion  
As previously reported16, 17, 10 serial cryosections (5um per section) of each tissue cube were 
incubated for 1h at 37°C in the presence of mouse anti-HSV1-gD antibodies (Santa Cruz, 
Heidelberg, Baden-Wurttemberg, Germany) (100mg/mL, 1:100 in 10% NGS) or mouse IgG2 as an 
isotype specific negative control antibody (Dako, Glostrup, Region Hovedstaden, Denmark). 
Following three washings with PBS, the sections were incubated for a further 1h at 37°C in the 
presence of goat anti-mouse-Texas Red antibodies (Molecular Probes, Invitrogen, Belgium) (2 
mg/mL, 1:50 in 10% NGS).  
  Immunofluorescence-stained slides were evaluated for viral invasion by viewing at 630 
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magnifications using a fluorescence microscope (Axioplan 2, Carl Zeiss, Gottingen, Lower Saxony, 
Germany). All stained slides were evaluated by two independent observers, who were blinded to 
the tissue-treatment protocol and assessed the entire epithelium in each section by viewing up to 8–
10 adjacent fields. HSV1 invasion in each field was graded on a 5-point scale (0= epithelium not 
infected, 1 = epithelium superficially infected, 2= basal cells infected, 3 = basement membrane and 
HSV1 co-localization, HSV1 do not penetrate the basement membrane, 4 = HSV1 penetrated the 
basement membrane into the lamina propria). The mean of total scores in the ten sections on each 
slide was used as the final invasion score for each explant. 
 
Inflammatory cytokines were measured by ELISA in tissue culture supernatants 
Inflammatory mediators IFN-γ, IL-6, IL-1β, TNF-α, IL-17, IL-5, IL-10 were measured in culture 
supernatants at baseline and at 24h, 48h and 72h after virus incubation by means of commercially 
available Quantikine ELISA kits (R&D Systems, Minneapolis, MN, USA). IFN-β (Invitrogen), 
IFN-α (Invitrogen), and IFN-λ (R&D systems, USA) release was measured in culture supernatants 
at baseline and at 24h, 48h and 72h after virus incubation, by using ELISA, according to the 
manufacturer’s instructions.  
 
Statistical analysis 
Data were expressed as median and interquartile ranges (IQR). The Kruskal–Wallis test was used 
to assess the significance of intergroup variability; the Wilcoxon test was used for paired 
comparisons, and the Mann–Whitney U 2-tailed test was used to assess significance for between-
group comparisons. P values < 0.05 were considered to be statistically significant. 
 
RESULTS 
Patient characteristics, cytokines and IgE levels in tissue homogenates   
The two groups of patients were comparable in terms of clinical characteristics, allergic status and 
comorbid disease. At baseline, tissues from CRSwNPs showed significantly higher total IgE, ECP 
and IL-5 concentrations vs inferior turbinate tissues from control samples (p<0.05). IL-17 was 
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 below detection limit in both groups, whereas IFN-γ could be detected in 3 control tissues (Table 
1). 
 
Table 1. Cytokines and IgE levels in tissue homogenates. 
 
BDL: below detection limit 
   
HSV1 replicates and invades in the nasal mucosal tissue after 24, 48 and 72 hours cultivation 
Infection of the nasal inferior turbinate mucosal tissue explants with HSV1 led to focal infection of 
outer epithelial cells within 24h (Figure 2A) with distribution up to the basement membrane and 
damage of epithelial structural integrity after 48 h (Figure 2B). Incubation of the tissue for 72h 
(Figure 2C) following inoculation with HSV1 led to infection of basal epithelial cells, followed by 
the loss of epithelium and subsequent invasion of HSV1 into the lamina propria. In contrast, HSV1 
infected the whole epithelium of nasal polyp tissue within 24h (Figure 2D), already causing 
epithelial damage after 48h (Figure 2E), and causing significant damage to the epithelium and 
invasion into the lamina propria through the basement membrane after 72h (Figure 2F). 
Tissue Detection limit 
after sample 
handling dilution 
 
Inferior turbinate 
healthy mucosal 
tissue (HMT)  
n=7, median 
(IQR) 
P value Chronic Rhinosinusitis 
with nasal polyps 
(CRSwNP) 
n=7, median (IQR) 
Total IgE 
(kUA/L) 
1.9 16.6 (9,24-42.3) 0.003 205.3 (56.4-244.2) 
ECP 
(ug/ml) 
11.0 357.5 (98-504.3) 0.015 13609.7(5236.3-20570) 
IL-5 (pg/ml) 7.0 BDL 0.007 263.7 (39.4-510.4) 
IFNγ (pg/ml) 42.9 42.9 (42.9-77.2) n.s BDL 
IL-17(pg/ml) 7.0 BDL n.s 7 (7-17.6) 
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  The depth of mucosal invasion for HSV1 in nasal polyp tissue was similar to turbinate mucosa at 
24h, but the invasion scores at 48 and 72h were significantly higher than those for the turbinate 
mucosa (p<0.05) (Figure 2G), indicating that more viruses infected deeper mucosal layers.  
Immunofluorescence staining for untreated cryosections was also performed by using anti-HSV1-
gD monoclonal antibodies. Neither in those cryosections nor in TCM treated HMT and CRSwNP 
tissues, HSV1 was detectable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Immunofluorescence-stained sections of inferior turbinate healthy mucosa tissue (HMT) 
and nasal polyp tissue samples (CRSwNP) after HSV1 infection. (A-C) HMT tissue was infected by 
HSV1 and incubated for 24h, 48h, 72h. (D-F) CRSwNP tissue was infected by HSV1 and incubated for 
24h, 48h, 72h. Isotype: mouse IgG2 antibody on the sections of the tissue samples after 24h HSV1 
infection. Red is the positive HSV1 signal. Invasion score of HMT and CRSwNP tissue samples by 
HSV1. Results are presented as mean scores + SEM for HMT from 7 patients and CRSwNP from 7 
patients. *P<0.01.  
 
Inflammatory mediator release after HSV-1 infection HSV1 induced a significant release of IL-
6 after 48h and 72h in both HMT and CRSwNP tissues, without significant difference between 
groups. However, in CRSwNP samples, we could demonstrate a significant release of IL-1β at 48h 
(p=0.031), whereas no IL-1β was released in HMT before 72h post inoculation (Figure 3A); the 
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concentration of IL-1β in the supernatants was significantly higher in CRSwNP compared to HMT 
at 72h (p=0.01). In line with these findings, the release of TNFα was significantly increased after 
48h (p=0.031) and 72h (p=0.031) in CRSwNP only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Inflammatory mediator release after HSV-1 infection. Inflammatory mediators IL-6, IL-1β, 
TNF-α, IFN-α, IFN-β, IFN-γ, IFN-λ, IL-5 and IL-10 were measured in infection model. Data were 
expressed as median and interquartile ranges (IQR) for HMT from 7 patients and CRSwNP from 7 
patients. * P value<0.05. TCM: tissue culture medium, indicating the uninfected culture.  
  IFN-α could be detected in 4 out of 7 HMT samples after HSV1 incubation at 24 and 48h, but not 
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in any CRSwNP samples; however, this difference did not reach significance. IFN-β was found in 
the supernatants of 3 HMT and 4 CRSwNP samples at 72h incubation. IFN-λ was not detectable at 
any of the time points in any of the samples. However, there was a significant increase of IFN-γ 
release in HMT samples at 48 (p=0.031) and 72h (p=0.016), but no induction of IFN-γ in CRSwNP 
tissue upon HSV1 infection (Figure 3B). 
  There were also significant differences in terms of T cell cytokine release in the response of 
CRSwNP and HMT to HSV1 infection (Figure 3C). The expression of IL-17 was only up-regulated 
in HMT tissues after 48 and 72h, but not in CRSwNP tissues. There was a significantly higher 
spontaneous release of IL-5 at 24 (p=0.037) and 48h (p=0.025) in CRSwNP vs. HMT, but this was 
independent from the impact of HSV infection. A significantly increased release of IL-10 was 
observed in CRSwNP vs. HMT at 48 (p=0.004) and 72h (p=0.004), which was further increased 
significantly by HSV1 infection at 72h (p=0.031). No increase in IL-10 was observed in HMT 
samples.  
Discussion 
This study shows for the first time a major difference in the response of healthy mucosa vs. mucosal 
tissue derived from chronic rhinosinusitis with nasal polyps (CRSwNP) in response to viral 
exposure, in this case HSV1. CRSwNP mucosal tissue shows a significant deficit in IFN-γ and IL-
17 release within 24 to 72h after infection in comparison to healthy mucosa, while at the same time 
releasing significantly higher levels of the pro-inflammatory cytokines IL-1β and TNF-α. These 
findings were associated with significantly higher viral invasion scores at 48 and 72h in CRSwNP 
mucosa compared to those for the healthy mucosa, indicating that CRSwNP nasal tissue provides 
less antiviral activity and at the same time releases disease progressing factors, allowing HSV1 to 
easier penetrate and spread through CRSwNP tissues, although the viral replication was similar 
between tissues.  
  Mucosal environments in disease are characterized by a distinct set of cytokine profiles, which 
impact on the extracellular matrix including the basement membrane, the type of inflammation 
(neutrophil/eosinophil), the innate and adaptive immune responses to microorganisms, and finally 
the potential to resolve ongoing inflammation18. Mucosal inflammation in nasal polyps mainly is 
orchestrated by Th2 cytokines, characterized by an increased eosinophilic inflammation and 
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formation of IgE antibodies. This endotype is associated with co-morbid asthma15 as well as 
recurrence of disease in Caucasian patients19. All 7 CRSwNP samples in this study were classified 
as IL-5 positive, with high IgE and ECP concentrations, and 2 out of 7 nasal polyp patients had mild 
asthma. This biochemical and clinical presentation contrasts to the healthy mucosa and asthma 
status of the control patients. The specific immune profile in Th2-biased CRSwNP has also been 
associated with defects in innate or adaptive immunity, such as the alternative activation of 
macrophages, the suppression of T regulatory activity20,21, or the epithelial barrier tight junction 
molecule expression22, 23. 
  IFNs are critical for innate and adaptive immunity against viral, some bacterial and protozoal 
infections24. Type I IFNs (IFN-α and IFN-β) can be produced by all nucleated cells as the first line 
of host antiviral defense25. Type II IFN (IFN-γ), affects activities of macrophages, NK cells, 
dendritic cells (DC), and T cells by enhancing antigen presentation, cell trafficking, and cell 
differentiation and expression profiles, conveying antiviral signals from the innate to the adaptive 
immune response in order to fully activate host antiviral immunity26. Recently identified type III 
IFNs (IFN-λ1, IFN-λ2 and IFN-λ3) can induce antiviral activity in a variety of target cells that 
express the IFN-λ receptor27. Aberrant IFN expressions are associated with a number of 
inflammatory and autoimmune diseases. An inadequate response to HRV infection has been 
recently described in severe asthma, suggesting that the innate anti-viral response to viruses, here 
HRVs, may be impaired in those patients28.  
  The significant release of IFN-γ in healthy mucosal tissue (HMT) samples at 48 and 72h is 
considered a normal response to a viral infection, whereas the lack of induction of IFN-γ release 
upon HSV1 infection in CRSwNP tissues may result in a deficit to limit viral replication. Our 
previous findings demonstrated that HSV1 has an increased invasive ability into nasal polyp tissue 
accompanied by more serious damage of epithelium compared with nasal turbinate mucosa16, 17. 
Also Type I and III IFNs have been shown to play an important role in combating HSV-1 infection, 
and studies have shown that the magnitude and swiftness of IFN-α/β induction correlates with the 
relative resistance of C57BL/6 mice to HSV-1 infection29. In this present study, IFN-α could be 
detected in 4 out of 7 HMT samples after HSV1 incubation at 24 and 48h, but not in any CRSwNP 
samples. IFN-β was found in the supernatants of 3 HMT and 4 CRSwNP samples at 72h incubation. 
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These findings were rather inconsistent and did not reach significance, but may point to a broader 
defect in IFN response in CRSwNP tissue.  
  IL-17 and related components of Th17 immune function are increasingly identified as 
contributors to the pathogenesis of many infections, including respiratory infections caused by 
viruses. IL-17 facilitates the recruitment of neutrophils to the airways, and contributes to the 
clearance of the virus. In our human nasal mucosa model, normal healthy controls responded with 
a significant increase in IL-17 release upon HSV1 infection, whereas CRSwNP tissue also lacked 
this adequate immune response with possible consequences; unfortunately, the recruitment of 
neutrophils cannot further be investigated in this model.  
  Structural cells such as epithelial cells form part of the first line of defense and play a key role in 
the initiation of the immune responses including the release of IL-1 family members early on during 
the development of the inflammatory cascade. Secretion of IL-1β is an important outcome of the 
inflammasome activation, involving NF-κB activation and the expression of pro-inflammatory 
cytokines29. In the present study, we could demonstrate a significant release of IL-1β and TNF-α in 
CRSwNP tissue, whereas no IL-1β was released in HMT before 72h post inoculation. This suggests 
that viral infection induces a more vivid inflammatory response in CRSwNP than in healthy control 
HMT. This observation is supported by a study reporting increased levels of the pro-inflammatory 
mediator IL-1β and one of its antagonists, IL-1 receptor antagonist (IL-1ra), in nasal lavage of 
asthmatic, but not non-asthmatic patients during experimental rhinovirus infection30. Wang et al 
showed no difference in IL-6 and IL-8 release in healthy mucosa vs. nasal polyp tissue after HRV 
infection in-vitro31; in agreement with their findings, we also found no difference for IL-6 (IL-8 was 
not measured here), but well for other cytokines, prominently for type 2 IFN, IL-17, IL-1β and 
TNF. 
  Herpes simplex virus (HSV)-specific T cells are essential for viral clearance. However, T cells 
do not prevent HSV during latent infection or reactivation. A recent study using PBMCs has shown 
that HSV-infected T cells stimulated through the TCR selectively synthesized IL-10, a cytokine that 
suppresses cellular immunity and favors viral replication32. This finding further was supported by 
studies in mice showing that the immunoregulatory cytokine IL-10 is a key host factor in inducing 
and maintaining T cell exhaustion, facilitating viral persistence33,34. In fact, 9% of human nasal 
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polyps were infected with HSV110, and persistent infections may contribute to this number. This 
hypothesis requires further research, focusing on IL-10 is a key player in the establishment and 
perpetuation of viral persistence. 
  As it is unethical to remove healthy ethmoidal mucosa from a non-diseased person, and it is 
seldom indicated to remove parts of the middle turbinate from healthy subjects; inferior turbinates 
have been used as controls for decades. We have shown in the past that inferior turbinates do show 
the same changes in terms of adaptive and innate immune reactions as the sinus mucosa in CRSsNP 
and CRSwNP35. In that sense we may expect that healthy inferior turbinates do represent healthy 
sinus mucosa. We assume that the structural changes from nasal polyps to normal sinus mucosa are 
much greater than the differences from ethmoidal to turbinate mucosa. However, we have to admit 
the fact that the tissue is isolated and the model therefore is not suitable for studies on cell migration.   
  In conclusion, we demonstrate here for the first time in a human ex-vivo mucosal model that the 
response upon viral infection by HSV1 of tissues derived from nasal polyps of chronic rhinosinusitis 
(CRSwNP) patients vs. inferior turbinate of healthy subjects differs considerably. CRSwNP shows 
a significant deficit in IFN-γ and IL-17 response, but in contrast releases significantly higher 
amounts of the pro-inflammatory cytokines IL-1β and TNF-α, and IL-10. This inadequate response 
is associated with a deeper intrusion of the virus upon acute infection, but also may lead to a different 
acute inflammatory response in CRSwNP tissue. 
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CHAPTER 5 
ENHANCEMENT of FOXP3 IN HUMAN AIRWAY REGULATORY T CELLS INHIBITS TH2 
RESPONSE BY REGULATING THE SUPPRESSOR PROTEIN SOCS3 IN CRSwNP. 
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Abstract:  
Background: In persistent upper airway inflammation, the number of fork head box P3 (Foxp3)+ T 
regulatory (Treg) cells is reduced but the regulation of Foxp3 expression in Tregs is poorly 
understood. 
Objective: We investigated the interaction between SOCS3 and Foxp3 expression in the airway 
mucosa.  
Methods: Expression of SOCS3 and Foxp3 was measured in CRSwNP tissue and control tissue. 
Co-expression of SOCS3 and Foxp3 was evaluated in PBMC and in CRSwNP tissue. We also 
switched off and overexpressed SOCS3 in CRSwNP tissues and in PNAC-1 cell lines and examined 
the effect on Foxp3 expression.  
Results: SOCS3 gene and protein expression was up-regulated in inflammatory cells in airway 
mucosa, whereas Foxp3 gene and protein expression was down-regulated. Mucosal Treg cells co-
expressed both proteins. Switching off the expression of SOCS3 in human airway mucosa resulted 
in Foxp3 up-regulation, whereas inducing it in PANC-1 cells led to Foxp3 down-regulation. We 
also found that phosphorylation of STAT3 was decreased in inflamed mucosa, and we hypothesized 
that SOCS3 was responsible. Phosphorylation of STAT3 increased upon silencing SOCS3 
expression in inflamed mucosa and decreased upon SOCS3 plasmid transfection in PANC-1 cells.  
Conclusions: We demonstrate for the first time that SOCS3 and Foxp3 are co-expressed in Treg 
cells in human nasal mucosa, and that SOCS3 negatively regulates Foxp3 expression in human 
airway mucosa, possibly by phosphorylation of STAT3. Hence, SOCS3 could be a potential target 
for restoring Foxp3 expression in Treg cells in persistent mucosal inflammation. 
Introduction  
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition in the 
upper airways that is often accompanied by co-morbid asthma. Two different inflammatory patterns 
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have been described in CRSwNP: either a T helper cell (Th)2 bias or a mixed Th1 and Th17 cell 
preponderance. Both patterns are accompanied by a deficit in fork head box P3 (Foxp3)+ T 
regulatory (Treg) cells in European and Chinese patients1-4. 
 Foxp3+ Tregs play a critical role in immune regulation by maintaining peripheral self-tolerance, 
thereby preventing chronic inflammatory and autoimmune disease 5. A loss-of-function mutation in 
the Foxp3 gene in mouse and human models is associated with immunodysregulation, 
polyendocrinopathy, enteropathy, and X-linked syndrome5. Overexpression of Foxp3 in Th cells 
imparts on them a suppressive phenotype6. However, regulation of Foxp3 expression in Tregs is 
still poorly understood. The role of suppressor of cytokine signaling3 (SOCS3) protein in the 
development and function of Tregs remains controversial. SOCS3 expression in antigen presenting 
cells (APCs) indirectly suppresses the development of Tregs7. On the other hand, Foxp3 might 
interact with SOCS3 by binding to the promoter or to other regulatory sites8. SOCS3 mediates the 
suppression of Tregs proliferation and the suppression of Foxp3 and CTLA-4 by reducing IL-2 
levels 9. The inactivation of SOCS3 in CD4+ cells prevents development of the symptoms associated 
with asthma, such as airway eosinophilia in mouse models10. 
  The SOCS family of proteins is at present composed of eight members characterized by the 
presence of a Src homology 2 domain and a C-terminal conserved domain called the SOCS box11. 
SOCS proteins negatively modulate the activation of signal transducer and activator of transcription 
(STAT) in the Janus Kinase (JAK)-STAT signaling pathway, which mediates the cytokine negative 
feedback plural loops11. The binding of cytokines such as IL-6, IL-2, IL-23, IL-4, INF-γ and GH to 
their specific receptors stimulates the cross-phosphorylation of STATs to induce SOCS genes. The 
SOCS proteins in turn bind to a cytokine-receptor complex, degrade the complex by SOCS-box, 
and interact with JAK enzyme through their SH2 region. This results in decrease of phosphorylated 
STATs (pSTATs)11,12. SOCS3 protein acts mainly on the phosphorylation of STAT3 and STAT513. 
  In mouse models, SOCS3 protein is a major regulator of the IL-23–mediated Th17 response14. 
SOCS3 has an important role in balancing Th1/Th2 towards Th2-type not Th1 differentiation15. 
High levels of SOCS3 in mouse T cells were also shown to cause Th2 skewing and allergic 
responses15. 
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  We analyzed whether SOCS3 is involved in the regulation of Foxp3 expression in human nasal 
mucosal tissue of CRSwNP patients and studied the mechanisms of this interaction. We used human 
nasal mucosa as a model to investigate the regulatory role of SOCS3 in the deficit of Foxp3+ Treg 
cells. 
Methods: 
  Patients. Nasal tissue was obtained from 71 CRSwNP patients and 12 control patients at the 
Department of Oto-Rhino-Laryngology of the West China Hospital of Sichuan University, Chengdu, 
China. None of the patients had taken oral corticosteroids for at least two months and topical 
medication for at least four weeks before surgery. The diagnosis of nasal polyps was made according 
to European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2007 guidelines16. The 
inferior turbinates of patients with septal deviation were used as controls. Prior to surgery, the 
rhinosinusitis symptoms were evaluated by a physician on a 4-points scale of 0-3 (0=no symptom, 
1=mild symptom, 2=moderate symptom, 3=severe symptom) and polyps were graded by size and 
extent in both left and right nasal fossa, according to the Davos classification (0 to 4 per side). The 
clinic data of all the patients were shown in Table E1 in the Online Repository. The study was 
approved by the local Ethics Committee on Humans.  
Table E1. Patients characteristics and symptom scores 
  Controls CRSwNP 
Number of patients 12 71 
Age( years, range) 29.75(17-60) 38.2(17-66) 
Female/male 3f/9m 35f/36m 
Asthma in history 0/12 7/71 
Aspirin intolerance (history) 0/12 0/71 
Duration of symptoms (years, range) n.a. 8.0(0.5-28) 
Bilateral CT score (Lund-Mackay) n.a. 16.08(11-24) 
Bilateral polyp score (Davos) 0 4.16(2-6) 
Total symptom score 0.9(0-4) 4.7(2-10) 
Nasal congestion 0.8(0-3) 2.1(0-3) 
Sneezing 0 0.6(0-3) 
Rhinorrhea 0.2(0-1) 1.2(0-3) 
Loss of smell 0 0.8(0-3) 
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Experimentation of the West China Hospital, Sichuan University. Informed consent was obtained 
from all patients and healthy donors before sample collection.  
Immunohistochemistry and immunocytochemistry. The nasal tissues were fixed in 10% neutral 
buffered formalin and processed to paraffin. Sections of 4–5 μm were incubated overnight at 4°C 
with primary antibody against SOCS3 (1:100) (Cell Signaling Technology, Beverly, MA). The 
secondary antibody was anti-goat (Zhongshanjingqiao, Beijing, China). Positive cells were 
visualized with the diaminobenzidine chromogenic reaction. Quantitative analysis of the 
histological sections was performed by two independent observers who counted a total of 300 cells 
in 10 fields per tissue section from 12 controls and 12 CRSwNP patients. Additionally, the sorted 
Treg cells from PBMC of 3 healthy donors were fixed and incubated with anti-SOCS3 antibody 
(1:100). As control, the specimens were incubated with isotype antibody IgG. 
qRT-PCR. This was used to estimate the mRNA levels of SOCS3, Foxp3, STAT3 and STAT5A/B 
in 71 CRSwNP patients and 12 control patients. After extraction of total RNA by using RNeasy kit 
following the manufacturer’s instructions (QIAGEN GmbH, Hilden, Germany), cDNA was 
synthesized starting with 40 ng total RNA by using the Prime Script RT Reagent Kit (Takara, Dalian, 
China). Total RNA was quantified with RT-PCR by the iCycler iQ Real-Time PCR Detection 
System (BioRad, CA) using the following primer sequences: SOCS3 (5’-ATG GTC ACC CAC 
AGC AAG TT-3’; 5’-ACT GAG CAG CAG GTT CG C-3’), Foxp3 ( 5’-GAA ACA GCA CAT 
TCC CAG AGT TC-3’;  5’-ATG GCC CAG CGG ATG AG-3’), STAT3 ( 5’-GCA CAT TCA 
TGC TAA GAT TCA G-3’; 5’-TGA TGC TTT GTG TAT GGT TCC-3’), STAT5A (5’-CCA CAG 
ATG AAG CAA GTG GTC-3’; 5’-ATC GAG TAC ATG CTC ATG GTT C-3’), STAT5B ( 5’-
GAT GCC TTT TAC CAC CAG AGA C-3’; 5’-AGT AGC AGA CTC GCA GGG AAC T-3’). 
PCR amplification consisted of 40 cycles of denaturation at 95°C for 15 sec and annealing and 
extension cycles at 60°C for 45 sec each. The target product was detected by SYBR Premix Ex Taq 
II kit (Takara, Dalian, China). To normalize for transcription and amplification variations among 
the samples, three housekeeping genes were used: β-actin, hydroxymethylbilane synthase, and 
elongation factor 1. The relative quantities expressed were assessed by the Gene Expression Macro 
Version 1.1 software (BioRad Laboratories Inc). 
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Western blotting. Protein was extracted with the Protein Extraction Reagent (KaiJi, Shanghai, 
China) from the nasal tissue of 35 CRSwNP patients and 12 control patients. Protein concentration 
was measured by Bicinchoninic Acid Assay kit (KaiJi, Shanghai, China). The following antibodies 
were used for western blotting: anti-SOCS3 (1:700), anti-STAT3 (1:800), anti-p-Tyr-STAT3 
(Tyr705) (1:700), anti-STAT5 (1:600), and anti-p-Tyr-STAT5 (Tyr694) (1:600). All the above-
mentioned antibodies were purchased from Cell Signaling Technology. Anti-Foxp3 antibody (1 
μg/ml) was purchased from Abcam (Cambridge, United Kingdom). The HRP-conjugated secondary 
antibody (1:10000) was from Santa Cruz (Santa Cruz, CA). The relative band densities of the target 
protein to β-actin (Boaosen, Beijin, China) were estimated by Bio-Rad Quantity One Analysis 
Software (Bio-Rad, CA).  
Cell isolation. Primary mononuclear cells were isolated from the blood of 3 healthy donors by 
Ficoll-Hypaque density gradient centrifugation according to the standard protocol. Cells were plated 
at 2x106 cells/well in a 24-well plate and cultured at 37°C in 5% CO2 for 5 days in 1ml RPMI1640 
culture medium (Sigma, St. Louis, MO) alone or with recombination human IL-2 (10 ng/ml) and 
recombinant human IL-15 (10ng/ml) (Miltenyi Biotec, Bergisch Gladbach, Germany).  
Single cell suspension and flow cytometry. Single cell suspensions of human nasal mucosa were 
prepared as described 17. To analyze the co-expression of Foxp3 and SOCS3 proteins in Tregs, the 
cultured cells and single cells of CRSwNP tissue (n=3) were collected and incubated with anti-CD3-
PE-Cy, anti-CD4-PerCP-Cy5.5 and anti-CD25-FITC antibodies for 30 min. After fixation and 
permeabilization, the cells were stained intracellularly with anti-Foxp3-PE and a 1:100 rabbit anti 
human SOCS3 (Abcam, Cambridge, UK) for 30 min followed by goat anti-rabbit APC secondary 
antibody (Invitrogen, Merelbeke, Belgium) for 20 min. PBMCs from healthy donors were stained 
with anti-CD4-FITC, anti-CD25-PerCP-Cy5-5 (BD Biosciences, Erembodegem, Belgium) and 
anti-Foxp3-PE antibody (BD Biosciences) and Treg cells were sorted using standard protocols and 
a FACS Aria instrument (BD, Biosciences). 
RNAi experiments. Three SOCS3-specific siRNAs (siG0933161433, siG0933161455 and 
siG0933161508) and a negative control siRNA (siN058151221487) were synthesized (RiBo Bio, 
Shanghai, China) and the target sequence was validated (5’-GAC CCA GTC TGG GAC CAA G-
3’). The following sequences were used: SOCS3 sense, GAC CCA GUC UGG GAC CAA G dTdT; 
107 
 
SOCS3 anti-sense CUU GGU CCC AGA CUG GGU C TdTd. The transfection efficacy of siRNA 
in nasal polyp tissue was estimated by using siR-Ribo™ Transfection Control (siN05815122148) 
(RiBo Bio, Shanghai, China). The result is shown in Figure E1. More detailed information about 
transfection efficiency has been provided in the Methods E1 of the Online Repository. Nasal polyp 
tissue (n=5) was washed with PBS containing 100 IU/ml penicillin and 100 μg/ml streptomycin 
three times and sliced into cubes. The 80 mg of tissue cubes were placed into each well of a six-
well plate containing 1.3 ml of RPMI 1640 medium and transfected with SOCS3-specific siRNA 
(40nM) or negative control siRNA (40nM) using 5 μl of the lipofectamine 2000 transfection reagent 
(Invitrogen, Carlsbad, CA) according to the standard protocol. After 4h of incubation, fetal serum 
(10% final concentration) (Hyclone, Logan, UT) was added to each well to terminate transfection 
and tissues were incubated at 37°C in humidified air with 5% CO2 for 48h. The tissue cubes were 
collected for RT-PCR and western blot. 
 
Figure E1: Transfection efficiency of siRNA in nasal polyp tissue fragments. The blue fluorescence 
represents the nuclei of cells, the green dots fluorescein-labeled siRNA transfection control. (A, B) 
Fluorescence images of nasal polyp tissue fragments without fluorescein-labeled siRNA. (C, D) 
Fluorescence images of CRSwNP tissue fragments with fluorescein-labeled siRNA. The merged version 
of green and blue fluorescence indicates the siRNA intracellular location (white arrows). Magnification: 
100× (A, C) and 400× (B, D). 
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Transient expression of SOCS3 in PANC-1 cells. Human pancreatic carcinoma epithelial-like 
cells (PANC-1), a cancer cell line with strong gene expression of Foxp318, was used for transient 
expression of SOCS3. pEF-FLAG-I/m vector and pEF-FLAG-I/m SOCS3 plasmid (2μg) were 
separately transfected into 5×106 PANC-1 cells by using lipofectamine 2000 transfection reagent. 
Total RNA and proteins were extracted from transfected PANC-1 cells after 48 h of incubation. 
These experiments were repeated three times.           
Statistics. A one-way ANOVA test, Mann-Whitney test and T test were performed using SPSS 12.0 
(SPSS, Inc, Chicago). A p value < .05 was considered statistically significant. 
Results: 
SOCS3 expression is increased in patients with CRSwNP. Immunohistochemical analysis 
showed that CRSwNP patients had significantly stronger expression of SOCS3 than controls 
(Figure 1). In CRSwNP tissue, SOCS3 protein was preferentially expressed in inflammatory cells, 
epithelium and submucosal glandular epithelium. Quantitative analysis of the histological sections 
performed by two independent observers showed a significant increase in SOCS3+ cells in nasal  
 
Figure 1 SOCS3 expression in CRSwNP tissues. Representative images of SOCS3 
immunohistochemistry in CRSwNP tissues (n=12) and controls (n=12). (A, C) SOCS3-positive cells 
(arrows) in controls. (B, D) SOCS3-positive stained cells (arrows) in CRSwNP. Magnification: 100× (A, 
B) and 400× (C, D). 
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polyp tissue, in which 33.3 ±9.06% of the cells were positively stained, as compared to only 6.67 
±3.58% controls (P<.0001). The levels of SOCS3 gene expression were higher in CRSwNP, and 
this was confirmed by western blot (Figure 2A, C). Importantly, the expression of Foxp3 protein 
in CRSwNP was significantly increased (Figure 2 B, D). 
 
 
Figure 2 The expressions of SOCS3 and FOXP3 in CRSwNP. (A) RT-PCR showing SOCS3 
expression in CRSwNP (n=71) and controls (n=12). (B) Western blotting pictures for SOCS3 and 
FOXP3 proteins in CRSwNP (n=35) and controls (n=12). (C) Quantification for SOCS3 protein in 
CRSwNP tissues. (D) Quantification for Foxp3 protein in CRSwNP tissues (*P<.05, **p<.01). 
 
 
Foxp3-positive Tregs express SOCS3 protein. In non-stimulated conditions, 86% of 
CD4+CD25+Foxp3+ Tregs in human peripheral blood expressed SOCS3 (Figure 3A-b). In PBMCs 
treated with 10 ng/ml of IL-2 and IL-15 for 5 days (Figure 3A-c), 96% of CD4+CD25+Foxp3+ Tregs 
co-expressed SOCS3. Therefore, most CD4+CD25+Foxp3+ cells co-expressed SOCS3 in both 
stimulated and non-stimulated conditions. In addition, CD4+CD25+Foxp3+ cells were sorted from 
PBMCs of three healthy donors and stained with anti-SOCS3 antibody. The result confirmed the 
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co-expression of these proteins in 96% of Tregs (Figure3B). In human nasal mucosal tissue of 
CRSwNP patients, 45.1% of CD3+CD4+CD25+cells were SOCS3+Foxp3+ (Figure 3C).  
 
Figure 3 The expression of SOCS3 and FOXP3 proteins in Treg cells. PBMCs of healthy donors 
gated on living CD3+CD4+CD25+Foxp3+ cells cultured in RPMI: (A-a) is the isotype control. (A-b) Non-
stimulated. (A-c) Stimulated with IL-2 and IL-15. (n=3) (B) CD4+CD25+Foxp3+cells sorted from 
PBMCs of healthy donors and stained with anti-SOCS3 antibodies. (n=3) (C) The single cells of 
CRSwNP tissue gated on living CD3+CD4+CD25+Foxp3+SOCS3+cells. (n=3) 
 
Modulation of SOCS3 levels and Foxp3 expression. As immunohistochemical analysis showed 
high levels of SOCS3 in epithelium, glandular epithelium, and inflammatory cells in CRSwNP 
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tissue, human nasal mucosal tissues were used in silencing experiments. Three different SOCS3-
specific siRNAs were designed to block the function of SOCS3 protein. The siRNA construct that 
knocked down SOCS3 protein most efficiently was selected. Blocking SOCS3 gene expression by 
siRNA decreased SOCS3 gene expression by 60% (Figure 4A). Analysis of Foxp3 gene expression 
after blocking SOCS3 expression demonstrated a three-fold increase in the same samples of 
CRSwNP tissue (Figure 4A). The RNA expression results were confirmed by western blot analysis: 
Foxp3 protein expression increased significantly upon silencing SOCS3 in CRSwNP tissue (Figure 
4 B, C).   
   The levels of SOCS3 mRNA and protein were increased in PANC-1 cells upon transfection with 
the SOCS3-encoding plasmid (Figure 4D-F), while Foxp3 protein expression was attenuated by up 
to 80%, as evident from measuring the relative expression levels by western blotting (Figure 4E). 
Taken together, our data demonstrate that SOCS3 negatively modulates Foxp3 expression.  
 
Figure 4 SOCS3 regulates FOXP3 expression in CRSwNP tissues. (A-C) SOCS3 and Foxp3 
expression in CRSwNP (n=5) upon addition of lipofectamine 2000 (lipo), transfection with negative 
control of siRNA (nc), or with SOCS3-specific siRNA (siRNA). (D-F) SOCS3 and Foxp3 expressions 
in PANC-1 cells upon addition of lipo, transfection with pEF-FLAG-I/m vector (vector) or pEF-FLAG-
I/m SOCS3 plasmid (plasmid) (n=3) (*P<.05, **p<.01). 
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SOCS3 regulation of Foxp3 might depend on the presence of pSTAT3. To further study the 
regulation of Foxp3 expression by SOCS3, the expression of STAT3 and STAT5A/B genes were 
investigated in the nasal tissue. STAT3, STAT5B and STAT5A gene expression were not different 
between CRSwNP and control tissue (data not shown). However, SOCS3 might attenuate the 
phosphorylation of STATs (pSTATs), which are the activated forms of STATs in the JAK-STAT 
pathway. We demonstrate that pSTAT3 was significantly down-regulated in nasal mucosa of 
CRSwNP patients in comparison with controls (Figure 5 A, B). The levels of STAT5 and pSTAT5 
proteins were undetectable in western blots. As shown in Figures 5 C and D, the relative expression 
of pSTAT3 was up-regulated by 65% after silencing SOCS3 protein expression in nasal mucosal 
tissue. In contrast, the relative expression of pSTAT3 was decreased by 75% when SOCS3 was 
overexpressed from a plasmid (Figure 5 E, F).  
 
Figure 5 The role of pSTAT3 in regulation of FOXP3. (A-B) pSTAT3 expression in nasal tissue. (C-
D) pSTAT3 expression in CRSwNP (n=5) upon addition of lipofectamine 2000 (lipo), transfection with 
negative control of siRNA (nc), or SOCS3-specific siRNA (siRNA). (E-F) pSTAT3 expression in 
PANC-1 cells upon addition of lipo, transfection with pEF-FLAG-I/m vector (vector), or pEF-FLAG-
I/m SOCS3 plasmid (plasmid) (n=3) (*P<.05, **p<.01). 
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Discussion: 
Chronic rhinosinusitis with nasal polyp is characterized by a Th2-skewed eosinophilic inflammation 
in European patients and by a Th17-biased inflammatory profile in Asian patients. However, 
regardless of the inflammatory profile, significantly weaker Foxp3 mRNA expression and 
significantly stronger T-bet and GATA-3 mRNA expression was observed in both groups of 
patients3. The mechanisms of altered T cell plasticity in CRSwNP are not yet clear. We propose that 
SOCS3 protein is an important regulator of Foxp3 in CRSwNP. We have demonstrated increased 
levels of SOCS3 protein in CRSwNP compared to controls. The expression of SOCS3 protein was 
mostly observed in inflammatory cells, epithelium, and glandular epithelium in the submucosa. 
  Importantly, SOCS3 expression is not limited to T effector cells14,15. Also CD4+CD25+Foxp3+ T 
regulatory cells stained intensely for SOCS3. To our knowledge, this is the first study to demonstrate 
the co-expression of SOCS3 and Foxp3 proteins in Tregs from human nasal mucosal tissue. In 
contrast, Pillemer et al.9 did not find SOCS3 protein expression in mouse Tregs. However, in mice 
lacking SOCS3 expression in T cells, a preferential Th3 and Treg differentiation was observed19,20. 
This T cell polarization bias could be explained by increased production of IL-10 and TGF-β in 
conditions of SOCS3 deficiency. In addition, the impaired expression of SOCS3 in APCs indirectly 
induces the promotion of CD4+CD25+Foxp3+ cells7. In recent experiments, Nguyen et al. showed 
that induction of SOCS3 expression in Tregs by pharmacologic means abrogated a Treg 
proliferative response induced by serum amyloid A and monocytes21. However, the mechanism of 
SOCS3–Foxp3 interaction and its role in Treg development are not completely understood.   
  The role of SOCS3 protein in T cell differentiation and function is well established22, but its role 
in Treg function is just being elucidated. The differentiation and survival of Tregs are regulated by 
Foxp3. The NF-κB family members, CREB/ATF, ETS-1 and FOXO1/3, were shown to facilitate 
Foxp3 transcription and to bind to its promoter and other regulatory elements, as reviewed23. 
Additionally, STAT3 and STAT5 phosphorylation is critical for Foxp3 induction in precursor cells24. 
Phosphorylated STAT3 and STAT5 were also shown to interact with the Foxp3 promoter and to 
modulate Foxp3 gene expression25. SOCS3 protein acts mainly via phosphorylated STAT3 and 
STAT526.  
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  In our RNAi experiments, abolishing SOCS3 expression in the nasal polyp tissue increased the 
levels of Foxp3. In contrast, when overexpression of SOCS3 was achieved by transient transfection, 
Foxp3 levels were down-regulated. These data confirm that in human nasal polyp tissue, SOCS3 
serves as a negative regulator of Foxp3 expression. Intranasal administration of Foxp3 strongly 
prevents the ovalbumin induced allergic airway inflammation in mice27. Moreover, up-regulation 
of Foxp3 by corticosteroids in asthmatic patients restores T regulatory cell function to suppress the 
Th2 response28. We therefore suggest that up-regulation of Foxp3 expression by SOCS3 down-
regulation might present a therapeutic approach in nasal polyps. In addition, we found that the levels 
of phosphorylated STAT3 protein are reduced in CRSwNP. We also confirm that phosphorylation 
of STAT3 increased upon silencing SOCS3 expression in inflamed mucosa and decreased upon 
SOCS3 overexpression from a plasmid transfected in PANC-1 cells. The regulatory role of pSTAT3 
on Foxp3, unlike pSTAT5, is still controversial. pSTAT3 is reported to play a negative role on 
Foxp3 in allergic or graft-versus-host mice models29,30, however, pSTAT3 signaling also can 
promote Foxp3 expression in the same graft-versus-host mice model25. Furthermore, induced Foxp3 
in human Treg cells is pSTAT3 dependent31, which is in accordance with our results in human nasal 
polyp tissue. Consequently, we suggest that phosphorylation of STAT3 might be involved in the 
SOCS3-induced regulation of Foxp3.  
The following limitations have to be taken into account: In this study we used CRSwNP patients 
from China, and there is evidence that Chinese nasal polyps are different from Caucasian polyps, 
so that our findings might not be readily transferable to all patients; however, there is evidence that 
the same down-regulation of Foxp3 applies to both the Chinese and the Caucasian polyps, and we 
also demonstrated that up-regulation of SOCS3 can be demonstrated in Caucasian polyp tissue (data 
not shown). We therefore believe that our data is valid for all nasal polyp patients. Our patients were 
asked to stop taking oral corticosteroids for at least two months and topical medication for at least 
four weeks before surgery; however, we had no possibility of controlling compliance. Also, we 
speculated on a possible therapeutic effect of silencing SOCS3 to increase the activity of Foxp3 
regulatory T cells, which might then lead to a suppression of the inflammatory process, but have 
not yet proven this here; further studies are ongoing. We also noticed that there is a difference in 
percentage of Foxp3 expression in SOCS3 positive cells in nasal polyp tissue vs. PBMC from 
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healthy donors. It is currently unclear whether this difference is due to the fact that we compare 
peripheral blood to tissue or healthy to diseased patients; further studies are needed to investigate 
this question. 
  In summary, we demonstrate that SOCS3 negatively regulates Foxp3 expression in CRSwNP, 
and this regulation may involve pSTAT3. As down-regulation of SOCS3 leads to an increase in 
Foxp3 expression, this might improve the suppressive capacities of Tregs32. Therefore, SOCS3 
could be a potential target for restoring Foxp3 expression in Treg cells to consecutively suppress 
persistent mucosal inflammation. Thus, SOCS3 siRNA or other promising therapeutic technology 
such as SOCS3 specific DNAzyme, a new class of antisense molecules that combines the specificity 
of DNA base pairing with an inherent RNA-cleaving enzymatic activity33, could possibly be used 
to inhibit SOCS3 expression for therapeutic intervention in nasal polyp disease.  
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Methods E1:  
Nasal polyp tissue was cut thoroughly in tissue culture medium consisting of RPMI 1640 and 
antibiotics (50IU/ml penicillin and 50μg/ml streptomycin). The tissue was passed through a mesh 
to achieve comparable fragment. Tissue fragments (±0.9 mm3) were re-suspended and pre-incubated 
in tissue culture medium for 1 h. 80 mg of tissue fragments were placed into each well of a six-well 
plate containing 1.3 ml of RPMI 1640 medium without antibiotics. Fluorescein -labelled siRNA, 
siR-Ribo™ Transfection Control (40 nM), was transfected into the tissue by using 5 μl of 
lipofectamine 2000 transfection reagent. After 4h of incubation, fetal serum (10% final 
concentration) was added to each well to terminate transfection and tissues were incubated at 37°C 
in humidified air with 5% CO2 for 48h. Tissue fragments with or without fluorescein-labeled siRNA 
were washed for three times by PBS before collection, frozen and prepared for cyrosections. 5μm 
thickness cryosections were fixed in 70% ethanol and dried at room temperature, prior to being 
mounted with DAPI (1:50 dilution). The transfection efficiency was evaluated by the formula: 
transfection efficiency=cells expressing green fluorescence/total accounted cells *100%. Images 
were obtained with two magnifications (100×, 400×) by a fluorescence microscopy (Axioplan 2, 
Carl Zeiss, Gottingen, lower Saxony, Germany). 
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Supplementary experiment which has been done based on the previous findings: 
To further study the inflammatory response changes in CRSwNP tissue after SOCS3 silencing, 
inflammatory cytokines such as TNF-α, IL-5, IL-17, IFN-γ and IL-10 were measured in 
supernatants of CRSwNP tissue with SOCS3 siRNA transfection. All cytokines were assayed using 
Luminex xMAP suspension array technology in a Bio-Plex 200 system (BioRad, MI, USA), and 
the final data was expressed as pg/ml. The protein level of IL-5 decreased in the CRSwNP tissue 
48h after silencing SOCS3 expression. To our Surprised, IL-10 cytokine also decreased after 
silencing SOCS3 expression in CRSwNP tissue. Although SOCS3 is very important for Th17 cell 
generation and IL-23–mediated Th17 response, no significant changes of IL-17 expression were 
observed in CRSwNP tissue with SOCS3 silencing (Figure 6). Thus, we confirm that blocking 
SOCS3 expression restores Foxp3 expression in Treg cells and inhibits Th2 response in persistent 
mucosal inflammation. 
 
 
 
 
 
 
 
 
 
 
Figure 6: Blocking SOCS3 expression inhibits Th2 response in CRSwNP tissue. Cytokine 
expressions in supernatant of CRSwNP tissue with SOCS3siRNA transfection. (*P<.05, **p<.01) 
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CHAPTER 6 
 
 
 
DISCUSSION AND PERSPECTIVES 
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Chronic rhinosinusitis (CRS) is an ill-defined umbrella term for sinus diseases. CRS is defined as 
disease of the nose and the paranasal sinuses that lasts for three months or longer before the doctor’s 
interview. The disease affects 15% of the total population in the United States; a recent European 
survey reports a prevalence of 10.8%1. However, CRS is not one disease, but distinct 
pathophysiologies have been described in different CRS subgroups. CRS without nasal polyposis 
(CRSsNP) often displays a Th1 based neutrophilic inflammation, while CRS with nasal polyposis 
(CRSwNP) in Europe is in approximately 80% of all cases dominated by Th2 driven eosinophilic 
inflammatory mechanisms, and may be accompanied by aspirin sensitivity and asthma 2, 3. Recently, 
our group has confirmed that the colonization with Staphylococcus aureus (S. aureus) and the 
presence of S. aureus enterotoxin-specific IgE antibodies significantly increase in the mucosa of 
CRSwNP subjects in comparison with control or CRSsNP patients. This suggests a link between S. 
aureus colonization or infection and a Th2 response. 
S. aureus induces a type 2 response in CRSwNP via epithelial cell derived cytokines 
In Chapter 3, we have focused on the association between S. aureus and the Th2 response in 
CRSwNP tissue. Critically, staphylococcal enterotoxin B (SEB) induces considerable release of pro-
inflammatory and Th2-associated cytokines including IL-4, IL-5 and IL-13 in human nasal and in 
mouse bronchial tissue4, 5. However, the role of S. aureus independent of enterotoxins in inducing 
type 2 immune responses in human chronic airway disease has not been elucidated. Thus, we used 
a S. aureus strain, which does not produce S. aureus enterotoxins in our infection model. Nasal 
epithelial cell lines or primary epithelial cells and certain microbial pathogen surrogates are 
frequently used to understand the post-infection immune response. However, as a bridge between 
simple cell lines and complex in vivo environments, nasal tissue explants are better suitable than 
primary epithelial cells or airway cell lines to investigate the role of microbes in airway diseases. 
These models can efficiently reflect the in vivo situation in the nose during infection. 
In recent years, it has been shown that cytokines derived from epithelial cells such as IL-33 and 
thymic stromal lymphopoietin (TSLP) released by various stimuli, are critical in propagating Th2 
immune responses6, 7. Our human nasal ex vivo infection model suggests that IL-33 and TSLP can 
be induced in CRSwNP tissue in the presence of S. aureus. Although TSLP is also induced in healthy 
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inferior turbinate (IT) tissue after S. aureus infection, a consequent IL-5 protein release is 
propagated in CRSwNP tissue only, not in healthy IT tissue. Therefore, CRSwNP tissue and IT 
tissue show different reactions upon S. aureus infection. Besides the increased IL-33 and TSLP 
expression, the receptors of epithelial cell derived cytokines TSLPR and ST2L were significantly 
up-regulated 48h after S. aureus infection, reinforcing the signal of epithelial cell derived cytokines. 
To analyze the following Th2 response, we measured the mRNA and protein level of IL-4, IL-5 and 
IL-13 cytokines in human nasal ex vivo infection model. We successfully demonstrated that the S. 
aureus strain without enterotoxin secretion can directly induce IL-5 and IL-13 in CRSwNP tissue, 
but did not find IL-4. To evaluate the specific role of S. aureus in IL-5 release, S. epidermidis was 
also included in the models. Our data unveiled that type 2 cytokines can only be induced by S. 
aureus, not by S. epidermidis in CRSwNP tissue. 
As S. aureus could induce TSLP and IL-33 in our human nasal ex vivo infection model, we also 
explored the pathway of cytokine productions induced by S. aureus. We could show that activation 
of the NF-κB pathway was evident from an increase in phosphorylation of P50 and P65 at early 
time points in BEAS-2B cells after S. aureus exposure, accompanied by an increase of IL-33 and 
TSLP release. The novel TLR2 antagonist CU-CPT22 inhibited the phosphorylation of P50 and P65. 
Consequently, the expression of the downstream IL-33 and TSLP decreased in a dose-dependent 
manner. Thus, S. aureus can directly induce epithelial cell-derived cytokine release via binding to 
TLR2 and consecutively propagates type 2 cytokine expressions in CRSwNP tissue (Figure 1).  
 
 
 
 
 
 
Figure 1: Staphylococcus aureus induces Th2 responses via epithelial cell derived cytokines TSLP 
and IL-33 in a nasal ex vivo infection model. 
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C. Bachert first described IgE to S. aureus enterotoxins in CRSwNP and confirmed its role as a 
marker of severe inflammation in the upper and lower airways, supporting the role of S. aureus in 
CRSwNP tissue8. However, the current work for the first time studies direct effects of S. aureus on 
Th2 cytokine induction independent of enterotoxin activity. The defense mechanisms against S. 
aureus may be impaired in CRSwNP, with a high rate of alternatively activated macrophages in 
CRSwNP vs. healthy mucosa, not suited to phagocytize and kill S. aureus efficiently9. Products of 
S. aureus, specifically superantigens, induce Th2 cytokines in CRSwNP and healthy mucosal tissue; 
however, these products need to be in direct contact with the immune cells. Thus, the presence of S. 
aureus within the mucosal tissue of CRSwNP patients may lead to persistent inflammation, but it 
remains unclear whether S. aureus - extra- or intramucosally - actually can initiate type 2 disease. 
In addition, we here elaborate that S. aureus induces Th2 cytokines via epithelial cell derived 
cytokines after binding to the TLR2 receptor. IL-5 release was not totally blocked by TLR2 blockage, 
indicating that another production pathway via which S. aureus induces the epithelial cell derived 
cytokines to propagate Th2 cytokines could be involved and needs to be unraveled. From our 
findings listed above, more efficient therapeutic interventions like specific eradication of S. aureus, 
blocking TLR2 receptor expression, TSLPR and ST2L expression and using specific antibody 
neutralization of TSLP and IL-33 in CRSwNP are perspectives for the further investigations. 
 
Th2 biased upper airway inflammation is associated with an impaired response to viral 
infection with Herpes simplex virus 1   
Viral infections are known as the most frequent cause of acute rhinitis and asthma exacerbations in 
children and adults. A high frequency of human rhinovirus (HRV) was found in epithelial cells 
scraped from the middle nasal meatus of CRSwNP patients; natural and experimental rhinovirus 
infections have been well studied in the lower airways. However, little is known about the effect of 
viral infections in patients with chronic inflammatory disease such as CRSwNP. It is also reported 
that 8% (2/23) of human CRSwNP tissues may be infected with herpes simplex virus 1 (HSV1) at 
a given moment in time10. Moreover, the nasal mucosa is considered the primary site of herpes virus 
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replication. In Chapter 4, nasal tissues were infected with HSV1 for 24, 48 and 72h to study the 
post-infection immune response in CRSwNP tissue. We here demonstrate for the first time that the 
depth of mucosal invasion for HSV1 in CRSwNP tissue at 48 and 72h was significantly higher than 
that in IT mucosa. Simultaneously, CRSwNP mucosal tissue showed a significant deficit in IFN-γ 
and IL-17 release within 24 to 72h after HSV infection compared to healthy mucosa, at the same 
time releasing significantly higher levels of the pro-inflammatory cytokines IL-1β and TNF-α. 
These findings indicate that CRSwNP nasal tissue provides less antiviral activity and at the same 
time releases disease progressing factors, allowing HSV1 to penetrate and spread easier through 
CRSwNP tissues. With the viral infection, also S. aureus has been shown to intrude into the nasal 
mucosa; the virus here works as a “door opener” for a germ which can further stimulate and maintain 
type 2 inflammation11. This might be a crucial mechanism which allows S. aureus to reside 
intramucosally and grants an enormous advantage to this germ. We could confirm that CRSwNP 
mucosal tissue exerts a defective defense ability against HSV 1 in comparison with controls. 
Although a high prevalence of HSV1 is observed in upper airways, HRV is one of the most common 
viruses in human airways and is associated with the development and exacerbation of asthma12. 
HRV infections induce IL-33 production in vivo, which can further initiate type 2 cytokine release 
from Th2 cells or innate lymphoid type 2 (ILC2) cells13. Although HSV1 infections could not induce 
Th2 responses in CRSwNP tissue upon infection, the effect of HRV infections on CRSwNP disease 
and the relationship between HRV infection and Th2 responses clearly merits further investigations. 
 
Enhancement of Foxp3 in human airway regulatory T cells inhibits IL-5 release by regulating 
suppressor of cytokine signalling 3 in CRSwNP 
Two different inflammatory patterns have been described in CRSwNP: a Th2 bias or a mixed Th1 
and Th17 cell preponderance14. Regardless of the inflammatory profile in CRSwNP, a deficit in fork 
head box P3 (Foxp3)+ T regulatory (Treg) cells is observed in European and Chinese patients15. 
However, Foxp3 regulation in Tregs is poorly understood. In Chapter 6, we focused on the 
enhancement of Foxp3 expression in CRSwNP to alter T cell plasticity in CRSwNP.   
We started from an observation in nasal tissue showing that the levels of SOCS3 were 
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significantly higher in CRSwNP compared to controls. Moreover, the increased SOCS3 protein was 
predominantly located in inflammatory cells, epithelium, and glandular epithelium in the submucosa. 
Further immunofluorescence staining demonstrated the co-expression of SOCS3 and Foxp3 
proteins in Tregs from human nasal mucosal tissue. Although the role of SOCS3 protein in T cell 
differentiation and function is well established16, its role in Treg function is just being elucidated. 
In our SOCS3 RNAi experiments, abolishing SOCS3 expression in the nasal polyp tissue increased 
the levels of Foxp3. In addition, when overexpression of SOCS3 was achieved by transient 
transfection, Foxp3 levels were down-regulated. This SOCS3-based regulation may involve 
pSTAT3. The findings confirm our hypothesis that SOCS3 is able to regulate Foxp3 expression in 
CRSwNP, and we speculate on a possible therapeutic effect of silencing SOCS3 to increase the 
activity of Foxp3 regulatory T cells, which might then lead to a suppression of the inflammatory 
process. Thus, we measured Th1, Th2 and Th17 associated cytokines after silencing of SOCS3 in a 
RNAi experiment, and demonstrated that TNF-α, IL-5 and IL-17 decreased in CRSwNP tissue upon 
silencing SOCS3 expression. 
A deficit in Foxp3+ Treg cells is observed in European and Chinese patients15, thus restoration of 
the deficiency of Treg cells is regarded as a plausible strategy to modulate Th2 biased allergic airway 
disease. However, adoptive transfer of Treg cells does not provide satisfactory results as observed 
in an asthmatic mouse model when compared to induced Treg cells. In addition, a better 
understanding of Foxp3 regulation is useful for obtaining more iTreg cells in the periphery. In 
Chapter 6, we have elaborated that silencing SOCS3 increased the activity of Foxp3 regulatory T 
cells which then inhibited Th2 cytokine release in CRSwNP. This provides further perspective in 
the role of SOCS3 siRNA or other promising therapeutic technology targeting at SOCS3 expression 
in therapeutic interventions on the Th2 response in type 2 airway disease.  
General discussion: 
In this thesis, we have demonstrated that the presence of S. aureus in CRSwNP nasal mucosa 
provides the possibility to induce Th2 cytokines via epithelial the cell derived cytokines TSLP and 
IL-33, which may aggravate and maintain type 2 immune responses in CRSwNP tissue. CRSwNP 
furthermore shows a significant deficit in IFN-γ and IL-17 response, but in contrast releases 
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significantly higher amounts of pro-inflammatory cytokines IL-1β and TNF-α compared to healthy 
controls, and IL-10 upon virus HSV1 infection; CRSwNP tissue thus displays a deficit against viral 
infections, which may serve as a door opener for S. aureus and may allow this germ to invade into 
the nasal mucosa. In consequence, products of S. aureus can directly interact with local immune 
cells, with the potential to create a type 2 inflammatory environment with IgE production. The 
presence of IgE antibodies to S. aureus enterotoxins is a hallmark of disease severity not only in 
upper, but also lower airway disease. We here stress that apart from allergens, specific germs and 
viruses also may play a critical role in the induction of type 2 immune responses; those infectious 
agents are commonly associated with Th1 and Th17 responses. We assume that not one single event 
will be sufficient to initiate and certainly not to maintain Th2 inflammation, but rather that multiple 
hits are necessary over time, involving microbes, allergens and environmental factors (Figure 2), 
to create a persistent type 2 bias within the tissue. The impact of such events probably depends on 
the quantity of viruses and/or bacteria and the time course, e.g. high numbers of microbes may hit 
the airway mucosa during an acute infection, and low numbers may persistently exert pressure as 
colonizers, biofilm formers or intramucosal intruders. Furthermore, the immune status of the airway 
mucosa will make a difference, with a Th1/Th17 biased mucosa being more resistant to Th2 
response than an already Th2-biased inflammatory status. As we have discussed, these different T 
helper cell milieus may co-exist, and thus the balance among Th1, Th2, and Th17 responses may 
determine the course and speed of disease development. Finally, a Th2 response may establish itself 
within the mucosa, which leads to further negative effects; a Th2 bias induces an insufficiency to 
defend the mucosa against viral and bacterial infections, which further amplifies the inflammatory 
process.  
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 Figure 2. Multiple hits may initiate or maintain type 2 biased immune responses; SOCS3 offers a 
way to inhibit type 2 immune responses in airways. Low numbers of viruses and /or bacteria may 
persistently exert pressure as colonizers, biofilm formers or intra-mucosal intruders. High number of 
microbes may hit the airway mucosa during an acute infection and result in plenty of type 2 cytokine 
release. The balance among Th1, Th2, and Th17 responses, the status of the airway mucosa and the 
environment are also involved in Th2 biased immune response initiation or maintenance in the airways. 
The disturbed balance among Th1, Th2, and Th17 induced by microbial infections may be restored by 
Treg cells induced by SOCS3 silencing. HRV: human rhinovirus, HRSV: human respiratory syncytial 
virus, S. aureus: Staphylococcus aureus, Th: T help. Treg: regulatory T cell. SOCS3: suppressor of 
cytokine signaling 3. 
 
  Finally, we have elaborated that silencing SOCS3 increased the activity of Foxp3 regulatory T 
cells which then inhibit Th2 cytokine release in CRSwNP tissue. In addition, the further 
investigations to identify the suppressive function of Treg with SOCS3 silencing are also of interest. 
Regulatory T cells potentially suppress deleterious activities of effector T cells and maintain a state 
of tolerance against various stimuli such as bacteria and viruses in airway mucosa. The presence of 
S. aureus can induce Th2 cytokines in CRSwNP tissue. Therefore, we assume that enhancing the 
functions of Treg cell in CRSwNP tissue may be a potential approach to inhibit Th2 immune 
response induced by S. aureus. 
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